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POPULAR SCIENCE SUMMARY 
Deep in the lungs, gas exchange is happening with oxygen taken up in the bloodstream and 
carbon dioxide expelled to be breathed out. To reach these deep parts of the lung, the air is 
guided through a series of branching tubes forming the upper (nose cavity and trachea) and 
lower (bronchi and bronchioles) airways. The ability of these airways to contract and relax is 
very important for regulating the airflow and hence the ability of the lungs to exchange gases. 
Asthma is a disease of the airways which results in the airways contracting too much, too often. 
Reason is that airway contraction is more easily triggered compared to healthy airways. The 
resulting excessive narrowing leads to breathing difficulties. This obstruction of the airways is 
also called airway hyperreactivity. 
 
Inflammation in the airways is an important reason for airway hyperreactivity. This 
inflammation can be caused by for example air pollution or viruses. Another trigger is allergy. 
In this case the immune system gets activated by otherwise unharmful causes like dog dander 
or mite debris present in dust found in most houses (called house dust mites). This inflammation 
causes airways to contract and swell, making them narrower, just as for example when a finger 
gets inflamed and starts to swell. 
   
Many cells of the immune system play a role in allergic asthma, but one cell type is 
especially important: the mast cell. This guardian cell can be found in all places of the body 
that are in contact with the outside world, for example the intestines, the skin and the lungs. 
They normally help the body protect itself against bacteria and parasites. However, mast cells 
in the lung can also cause lung disease. This happens when a person with allergic asthma is 
exposed to for example house dust mites, causing mast cells to become wrongly activated. 
  
When mast cells become activated, they release different kinds of signalling molecules. 
Among these molecules are different kinds of lipid messengers. These are made by the body 
from polyunsaturated fats from food such as nuts or fish. Important lipid messengers are 
prostaglandins and leukotrienes. Prostaglandins are known for causing inflammation 
symptoms (pain, swelling, redness, heat) and fever. Drugs like ibuprofen put a brake on 
prostaglandin formation. That is why they are used during fever or inflammation. Leukotrienes 
are well known for their ability to make the airways contract, as some prostaglandins do as 
well. Because of this release of lipid mediators, mast cell activation can lead to inflammation 
and airway contraction. 
 
However, lipid messengers are not only involved in starting inflammation, but may also 
contribute to stopping inflammation. One such group of lipids is called specialised pro-
resolving mediators (SPMs) and the function of these SPMs is thought to be to put a brake on 
inflammation. This means that they block some inflammatory effects of other substances, but 
also activate certain parts of the immune system to clean up all the bacterial and dead cell debris 
after inflammation. This way the body can return to its normal, healthy state again. 
 
In this thesis it was investigated if a selection of SPMs could reduce airway 
hyperreactivity. If so, future medicines based on SPMs could be developed to relieve airway 
hyperreactivity in asthma, and so decrease hospital visits and increase the quality of life of 
patients. In addition, it was assessed what mechanism lies behind the observation that drugs 
like ibuprofen can worsen symptoms of asthma in certain patients. And finally, it was 
investigated whether lung mast cells were responsible for causing airway hyperresponsiveness 
and contraction when exposed to house dust mite extract.  
 
First, repeated exposure to an extract of house dust mites, but also TNFα and IL-13 were 
used to cause airway hyperreactivity in mice. TNFα and IL-13 are so-called cytokines and have 
important roles as a signalling molecule in the immune system. Second, when mice received 
certain SPMs together with house dust mite, TNFα or IL-13, the airway hyperreactivity was 
reduced. These mice were thus protected from airway hyperreactivity, in particular after 
exposure to the SPMs LXA4 and three cysteinyl maresins. A possible explanation for how 
lipoxins mediated these protective effects could be that lipoxins directly interfere with the 
ability of TNFα to signal to other cells in the airways. A receptor was found that might be 
important in the reducing effect of cysteinyl maresins, but the exact role of this receptor 
remained unclear. With our experiments it was shown that the tested SPMs are promising 
targets for future development of drugs to treat people with difficulties breathing due to 
increased airway contraction, e.g., in asthma. 
  
Additionally, it was discovered that not only SPMs had a protective function. Quite 
surprisingly, PGD2, mostly regarded as to cause inflammation, also had a braking effect on 
activation of mast cells. This effect was found by activating mast cells in guinea pig trachea. 
Mast cell activation caused the guinea pig trachea to contract due to release of many substances 
like histamine, cysteinyl leukotrienes and PGD2. But contrary to the other substances, the 
release of PGD2 made the tracheal rings actually contract less. Also, the dampening effect of 
PGD2 was lost when a specific receptor on mast cells, the DP1 receptor, was blocked. The 
proposed mechanism is as follows: when airways from sensitised guinea pigs are exposed to 
allergens, mast cells become activated. These activated mast cells release many inflammatory 
and constriction-causing substances. However, they also release PGD2 which puts a brake on 
the same mast cells to prevent them from releasing more substances that cause contraction. 
PGD2 thus helps mast cells to not to release too much of the contractile substances and 
ultimately prevents too much contraction of the airways. 
 
Finally, in mouse airways and lungs from mice made allergic to house dust mite, it was 
shown that the presence of mast cells was necessary to cause a contraction when exposed to 
house dust mite extract. Moreover, mast cells made airways more sensitive to contraction-
causing substances. This resulted in increased airway contraction compared to mice not allergic 
to house dust mite. Also, mast cells were activated by a substance released from nerves. It could 
therefore be that nerves present in airways influence how mast cells and airway contract when 
exposed to allergens like house dust mites. 
  
In conclusion, what was learned from these experiments is that: 
 
 
• House dust mite, TNFα and IL-13 cause increased contractions of airways. This 
increased contraction of airways can be reduced by lipoxins and cysteinyl maresins. 
 
• PGD2 does not only cause inflammation but also protects airways against excessive 
airway constriction. 
 
• Mast cells present in the lung trigger airway contractions and airway hyperreactivity 
when exposed to house dust mite, possibly through interaction with nerves present in 
airways.  
 
• Development of drugs that resemble SPMs or that are directed towards mast cells could 





Djip yn de minsklike long wurde gassen útwiksele. Koalstofdiokside wurdt út it bloed wei 
frijjûn oan de lucht dy’t útazeme wurdt. Soerstof giet krekt de oare kant op en wurdt út de 
ynazeme lucht wei opnommen yn it bloed. Om de djipten fan de longen te berikken, wurdt de 
lucht ferfierd troch in buizestelsel. Dat stelsel bestiet út de boppeste (noas en luchtpiip) en de 
ûnderste luchtwegen (bronkioalen en bronkiën). Om stjoere te kinnen hoefolle lucht at der yn- 
en útazeme wurdt, kinne de luchtwegen gearlûke en ûntspanne. Astma is in sykte wêrby’t de 
luchtwegen just tefolle en ta gau gearlûke. Dêrtroch rekket de pasjint benaud. Dat wurdt ek wol 
luchtweihyperreaktiviteit (LWH) neamd. 
    
LWH wurdt faak feroarsake troch ûntstekking fan de luchtwegen en longen. Dat soarte 
fan ûntstekking kin komme troch bygelyks firussen en luchtfersmoarging. In oare reden kin 
wêze dat it ymmúnsysteem aktivearre wurdt troch ûngefaarlike saken lykas hûnehierren en 
hússtofmyt. Myt is yn alle húshâldens oanwêzich en soarget gewoanwei net foar problemen. 
By allergyske ûntstekking lykwols, krekt as bygelyks by in ûntstutsen finger, swolle de 
luchtwegen op en wurde se smeller. Dat en dat se earder en krêftiger gearlûke, soarget derfoar 
dat it sykheljen hieltyd lestiger wurdt. 
 
In soad sellen spylje in rol yn it ûntstekkingsproses, mar in ekstra wichtige rol is der foar 
mêstsellen. Dy sellen kinne fûn wurde op alle plakken mei oerflakken dy’t yn kontakt steane 
mei de bûtenlucht, bygelyks de termen, de hûd en dus de longen. Gewoanwei helpe se om it 
lichem te beskermjen tsjin baktearjes en parasiten. Mar mêstsellen wurde ek aktivearre as in 
persoan allergysk is foar bygelyks hússtofmyt en astma hat. 
 
At mêstsellen aktyf wurde, begjinne se in grut ferskaat oan stoffen út te stjitten, wêrûnder 
fet-eftige boadskipperstoffen. In wichtige groep fetten binne de prostaglandines en 
leukotriënen. De prostaglandines feroarsaakje ûntstekkingssymptoanen lykas pine, tining en 
koarts. Dêrom wurde medisinen as ibuprofen ek brûkt, want dy remje de oanmaak fan 
prostaglandines yn it lichem. Leukotriënen soargje derfoar dat luchtwegen harren gearlûke, in 
effekt dat bepaalde prostaglandines ek hawwe. Dêrtroch liedt de aktivaasje fan mêstsellen ta 
ûntstekking en benaudens. 
 
Dochs binne dy feteftige stoffen fan mêstsellen net allinnich belutsen by it begjin fan 
ûntstekking, mar ek om dy wer del te bêdzjen. Dy groep wurdt mei in Ingelsk wurd ek wol 
specialised pro-resolving mediators (SPMs) neamd. Se dogge dat troch ûntstekkingseffekten 
fan oare stoffen te blokkearjen, mar se stimulearje ek oare parten fan it ymmúnsysteem om 
oerskotten fan baktearjes en deade sellen op te romjen. Sa kin it lichem wer werom nei syn 
normale, sûne steat. 
 
Yn dizze dissertaasje is ûndersocht of SPMs ek LWH ferminderje koene. At dat sa wêze 
soe, dan soene der yn de takomst medisinen fan makke wurde kinne foar astmapasjinten, sadat 
se minder nei it sikehûs ta hoege en in hegere kwaliteit fan libjen hawwe. Dêrneist hawwe wy 
ek ûndersocht oft in bepaalde prostaglandine - prostaglandine D2 (PGD2) - ek in beskermjende 
funksje hat. Yn it lêst hawwe wy ek ûndersocht oft mêstsellen echt nedich binne foar LWH 
troch hússtofmiten. 
 
Om dat te ûndersykjes waarden luchtpipen fan mûzen en bargemotten (kavia’s) brûkt. 
De luchtpipen kinne yn libben holden wurden yn in spesjale, iiskâlde buffer besteande út sûker 
en sâlten. Al it fetweefsel wurdt dan fuorthelle en de luchtpiip wurdt yn ringen knipt. De ringen 
wurde dan ophongen yn in myograaf. Dat apparaat bestiet út lytse putsjes dêr’t in waarme 
buffer yn sit (37 °C, lichemstemperatuer) en twa izeren pintsjes dêr’t de ringen omhinne dien 
wurde kinne. Sa kin mei help fan in kompjûter metten wurde hoe’t se gearlûke en wer 
ûntspanne. Yn de SPM-stúdzjes waarden de luchtpiipringen earst fjouwer dagen yn in 
ynkubator holden. Yn dy fjouwer dagen waarden stoffen dy’t ûntstekking en LWH feroarsaakje 
en SPMs tafoege. Dêrnei waard dan yn de myografen besjoen oft de SPMs ek in delbêdzjend 
effekt hiene op de LWH. 
 
Wat sjoen waard, wie dat in bepaalde groep SPMs, nammentlik de lipoksinen, yndie sa’n 
delbêdzjend effekt hie op LWH, feroarsake troch in ekstrakt fan hûsstofmiten en TNFα. TNFα 
is in saneamde sytokyne en soarget foar ûntstekking en LWH. Wat ek sjoen wurde koe wie dat 
de LWH nei bleatstelling oan hûsstofmytekstrakt kaam troch datselde TNFα, mar dan 
oanmakke troch it lichem sels. Mooglik dat de lipoksinen dus direkt de wurking fan TNFα 
blokkearje. 
     
It oare artikel oer SPMs wie konsintreare op in oare, nije groep SPMs. Dy binne bekend 
ûnder de namme systeinyl maresinen. Diskear wiene de rinkjes wer fjouwer dagen op kweek 
hâlden, mar no mei IL-13 as LWH-feroarsaakjende stof. IL-13 spilet in wichtige rol yn it 
sykteproses fan astma. Wat no wer sjoen waard, wie dat IL-13 yndie LWH feroarsake en ek 
dat de systeinyl maresinen dat delbêdzje koene. Eat dat it anti-astmamedisyn dexamethason net 
koe. Uteinliken is it net krekt dúdlik wurden hoe’t dy stoffen LWH delbêdzje, mar it is no wol 
dúdelik dat der in soad fan ferwachte wurde kin as it giet om de behanling fan astma. 
 
Unferwachts waard ek ûntdutsen dat PGD2 in beskermjende funksje hie. PGD2 wurdt 
makke en útstjitten troch mêstsellen fan bargemotten dy’t allergysk makke binne foar 
ovalbumine (OVA), in aaiwyt út hinneaaien. As OVA dan tafoege wurdt oan de buffer mei de 
rinkjes ûnder de eksperiminten, dan stjitte de mêstsellen stoffen út lykas histamine, systeinyl 
leukotriënen en dus PGD2. Lykwols yn tsjinstelling ta dy oare stoffen, soarge PGD2  der just 
foar dat de rinkjes minder gearlutsen. Dat die PGD2 troch te binen oan de mêstsellen wêr’t it 
weikaam. Dêrtroch  stjitten mêstsellen úteinlik minder stoffen út en luts de luchtpiip minder 
sterk gear. PGD2 is dus in wichtige stof fan mêstsellen dy’t derfoar soarget dat se net tefolle 
aktivearre reitsje en de luchtwegen hielendal tichtknipe. 
 
Op it lêst waarden der noch eksperiminten dien op mêstsellen yn mûzeluchtpipen . As dy 
mûzen allergysk makke wiene foar hûsstofmyt en se dêroan bleatsteld waarden, dan lutsen de 
luchtwegen gear. Wat toand waard wie dat dêr mêstsellen foar nedich binne. At dy net yn de 
long oanwêzich wiene, dan knypten de luchtwegen net gear by bleatstelling oan hûsstofmyt. 
Dêrnjonken waard ek dúdelik dat mêstsellen aktivearre wurde kinne troch in stof dy’t 
gewoanwei troch senuwen útstjitten wurdt. It soe dus sa wêze kinne dat senuwen in rol spylje 
yn hoe’t en wannear’t mêstsellen aktivearre wurde by bleatstelling oan allergenen lykas 
hússtofmyt. 
  
De konklúzjes dy lutsen wurde kinne, binne dus: 
 
• LWH, feroarsake troch hússtofmyt, TNFα en IL-13 kin delbêde wurde troch 
lipoksinen and systeinyl maresinen. 
 
• Mêstsellen yn de longen spylje in wichtige rol yn luchtweikontraksjes feroarsake troch 
hússtofmyt, mooglik troch ynteraksjes mei senuwen. 
 
• Dat makket SPM in oantreklik bestândiel yn nije medisinen tsjin benaudens. Fierder 
wurdt yn it ûndersyk it belang oantoand fan mêstsellen foar de ûntwikling fan nije 







Lipid mediators play an important role in responsiveness of the airways. The roles of 
prostanoids and leukotrienes in inducing airway inflammation and contraction are reasonably 
well established. The functions of specialised pro-resolving lipid mediators (SPMs), which are 
thought to mediate pro-resolving and anti-inflammatory effects, are less well-studied. The 
current knowledge on SPM functions, specifically in airway inflammation and contractility is 
limited. Furthermore, mast cells are important innate immune effectors cells found in the lung, 
known to release a host of pro-inflammatory and contractile cytokines and lipids in allergic 
airway inflammation and airway hyperreactivity. However, if the presence of mast cells in 
airways is necessary for antigen-induced airway contractions and induction of airway 
hyperreactivity remains to be clarified. In addition, though it is known that unselective cyclo-
oxygenase (COX)-inhibition results in increased contractions in airways upon mast cell 
activation by antigen, the exact mechanism behind this is unknown. The aim of this thesis was 
thus to investigate if selected SPMs have anti-hyperreactive properties, how COX-inhibition 
results in increased airway constriction and if mast cells are necessary for antigen-induced 
contraction and airway hyperreactivity.  
To this end, mouse and guinea pig models of airway hyperreactivity and allergic 
inflammation were used. Tracheae were dissected free from surrounding tissue and divided in 
segments of equal size. The isometric contractions of these isolated tracheal preparations were 
studied in myographs, either immediately after dissection from mice that received intranasal 
administration of HDM and SPMs beforehand, or after four days of incubation of the segments 
with cytokines and SPMs. Alongside this, concentrations of released mast cell mediators were 
determined with liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) 
and enzyme-linked immunosorbent assay (ELISA). 
First, it was found that four-day intranasal administration of the SPMs lipoxin A4 (LXA4) 
and resolvin D1 (RvD1) could reduce house dust mite (HDM)-induced airway hyperreactivity. 
The reducing effect of LXA4 was replicated when added during four days of incubation of 
tracheal segments with HDM and TNFα and was also present for lipoxin B4 (LXB4). A 
potential involvement of the ALX/FPR2 receptor was found, though this should be further 
backed up by future investigations.  
Second, IL-13 induced a steroid-resistant airway hyperreactivity in vitro that could be 
reduced by cysteinyl maresins. This effect could be blocked by three different cysteinyl 
leukotriene (CysLT) receptor 1 antagonists. However, LTD4 could not reproduce the anti-
hyperreactive effect nor did it interfere with cysteinyl maresin signalling. The exact receptor 
signalling remains to be clarified. 
Third, prostaglandin D2 (PGD2) was found to be produced by the COX-1 enzyme in mast 
cells present in tracheal segments from ovalbumin (OVA)-sensitised guinea pigs, when 
exposed to OVA in vitro. Further release of contractile mediators like histamine and cysteinyl 
leukotrienes from mast cells was inhibited by PGD2. This was done via the DP1 receptor, 
therefore PGD2 and the DP1 receptor likely function as an inhibitory, autocrine signalling axis 
for mast cells.  
Fourth, the presence of mast cells in lung tissue was necessary for HDM-induced airway 
contractions and mast cell absence led to reduced airway hyperresponsiveness in mouse 
models. Repeated HDM-exposure via intranasal instillation led to airway hyperreactivity 
mediated by carbachol and serotonin (5-HT) in isolated tracheal segments. The data suggest 
that mast cell activation occurred as an interplay between nerve-endings and mast cells, as 
mouse mast cells expressed the M3-receptor and activation led to release of 5-HT. 
To conclude, lipid mediators and mast cells play an essential role in the modulation of 
airway responsiveness. They do this by either inducing contractions after antigen-exposure 
(mast cells), reducing cytokine and antigen-induced airway hyperreactivity (SPMs) or 
inhibiting release of pro-contractile mediators and ultimately airway contractions (PGD2). This 
 
 
makes SPMs and their receptors, as wells as mast cells promising future drugs or drug targets 
for the treatment of airway hyperreactivity as seen in for example asthma. 
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LIST OF ABBREVIATIONS 
5-HT 5-hydroxytryptamine also know as serotonin 
5-HT2a 5-hydroxytryptamine 2a receptor 
AA Arachidonic acid 
AC Adenylyl cyclase 
AHR Airway hyperresponsiveness 
ALX/FPR2 Lipoxin A/formyl peptide 2 receptor 
COX Cyclooxygenase, also known as prostaglandin-endoperoxide 
synthase 
CpaCre/+ Mice that express Cre-recombinase instead of mast cell 
carboxypeptidase A3, i.e., mast cell devoid mice 
CysLT Cysteinyl leukotriene 
CysLT1 Cysteinyl leukotriene 1 receptor 
DHA Docosahexaenoic acid 
DP1 Prostaglandin D2 receptor 1 
Emax Maximal effect of a given agonist 
EPA Eicosapentaenoic acid 
HDM House dust mite 
IL Interleukin 
LOX Lipoxygenase enzyme 
LPS Lipopolysaccharide 
LXA4 Lipoxin A4 
MCTR Maresin-conjugate in tissue repair, also cysteinyl maresin 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
OVA Ovalbumin 
pEC50 Negative logarithm of EC50, which is the concentration needed 
to elicit half-maximum response 
PGD2 Prostaglandin D2 
PGE2 Prostaglandin E2 
PGF2α Prostaglandin F2α 
PGI2 Prostaglandin I2, also known as prostacyclin 
RvD1 Resolvin D1 
SPM Specialised pro-resolving mediator 




Increased contractility of the airways is a central pathophysiological component of asthma, 
making research into ways to dampen increased contractility highly relevant. Especially since 
in severe asthma, airway hyperreactivity or hyperresponsiveness (AHR) might be hard to 
control and leads to loss of quality of life, hospital visits and sometimes death. The central 
theme of this thesis is therefore hyperreactivity of airway smooth muscle under allergic 
inflammatory conditions and how lipid mediators can modulate this, i.e. have anti-
inflammatory and anti-hyperreactive actions.  
Prostanoids and leukotrienes have been studied over the decades since their discovery 
and generally induce inflammation or contraction of airway smooth muscle. This has also led 
to the successful development of cysteinyl leukotriene (CysLT) receptor antagonists such as 
montelukast, which are used in the management of asthma symptoms. However, the recent 
discovery of certain ω-3 and ω-6 polyunsaturated fatty acid products, called specialised pro-
resolving lipid mediators (SPMs), has opened the door to a whole new approach. An approach 
in which SPMs, SPM-derivatives or other agonists for their receptors might be used to actively 
resolve airway inflammation and symptoms of increased airway contractility.  
To aid in the development of possible future treatment strategies, mouse and guinea pig 
models were used to study the modulation of airway responsiveness. Cytokines and antigens 
were utilised to induce airway hyperreactivity or to study antigen-induced airway contraction 
via mast cells. These models made it possible to assess the anti-hyperreactive potential of 
SPMs, but also the exact role of mast cells in antigen-induced airway contractions and the mast 
cell-inhibiting potential of prostaglandin D2 (PGD2).   
The studies revealed that several groups of SPMs, namely lipoxins, cysteinyl maresins 
and potentially resolvin D1 (RvD1), have the ability to reduce airway hyperreactivity in mouse 
airways. Additionally, PGD2 was found to reduce antigen-induced mediator release and 
contractions in guinea pig airways. Lastly, lung mast cells were imperative for antigen-induced 




2 LITERATURE REVIEW 
2.1 INTRODUCTION 
Asthma is an inflammatory disease of the airways. Despite its name suggesting a clear, single 
disease, asthma is characterised by multiple endo- and phenotypes (1). Regardless of this 
heterogeneity, all asthma patients show symptoms such as wheezing, coughing and shortness 
of breath (2). On a tissue level, predominant characteristics of the condition include 
bronchoconstriction, airway inflammation, AHR, airway remodelling and increased mucus 
secretion (2).  
In airway allergic inflammation, mast cells and mast cell-derived mediators play an 
important role in the initiation of the inflammatory process and modulation of bronchial tone. 
Lipid mediators derived from ω-6 and ω-3 polyunsaturated fatty acids (PUFAs) are one group 
of mediators found in mast cells and other cells. They potentially play a role in the initiation, 
aggravation, and resolution of the asthmatic inflammatory response (3-6). Lipid mediators 
derived from ω-6 and ω-3 PUFAs can be divided in a more proinflammatory group: the 
prostaglandins, leukotrienes and thromboxanes and an anti-inflammatory and pro-resolving 
group: the lipoxins, resolvins, protectins and maresins, though exceptions exist (7).  
The importance of these lipid mediators in inflammation and asthma is illustrated by the 
clinical use of leukotriene antagonists in asthma, as well as findings which suggest that 
decreased levels of lipoxins contribute to the pathology seen in patients with severe asthma (4, 
8). 
2.2 REGULATION OF AIRWAY SMOOTH MUSCLE TONE  
2.2.1 Airway anatomy 
The human airway starts as a single compartment in the nasal cavity. Through the pharynx and 
larynx, this leads to the trachea. This large conducting airway has a length of approximately 13 
cm and a diameter of around 2 cm. The trachea is built up in distinct layers: an outer layer 
consisting of connective tissue and lymph nodes; horseshoe-shaped cartilage rings and 
interspersed smooth muscle tissue; a submucosa and an inner mucosal layer lined with 
epithelium. Further distal, the trachea bifurcates into two mainstem bronchi which further 
bifurcate again and enter the lung through the hila. The bronchi keep dividing and decrease in 
diameters <2 mm. These bronchi resemble the trachea, except for the cartilage rings which 
decrease in thickness and the diverse lung immune cells including resident macrophages, T-
cells and mast cells (9). Further distal, the airways are called bronchioles. These bronchioles 
terminate in alveoli, in which the actual gas-exchange takes place (10-12). 
2.2.2 The role of epithelium derived signals 
The inner mucosal layer of the upper and lower airways consists of pseudostratified columnar 
epithelium with apical cilia, interspersed with diverse secretory cells (13, 14). Within the 
airways, the epithelial layer fulfils several key roles. First and foremost, it acts as a barrier 
against micro-organisms, in particular bacteria and fungi, but also to prevent allergens and 
noxious gases reaching deeper tissue layers (15, 16). Secondly, when epithelium gets activated 
by a trigger, it can release different cytokines such as TLSP, IL-25 and IL-33. These cytokines 
stimulate the immune system and initiate and regulate eventual tissue repair and regeneration 
(16, 17). Thirdly, the epithelium has a function in the release of mediators, for instance nitric 
oxide (NO), prostaglandins and SPMs. These can induce biological effects such as modulation 
of airway smooth muscle tone, regulation of secretion of mucus or inhibition of histamine 
release by lung mast cells (18-20). Finally, the epithelium contains enzymes, e.g. 
acetylcholinesterase or monoamine-oxidase, which degrade contractile agonists such as 
acetylcholine and serotonin (5-HT) respectively (21, 22).    
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2.2.3 Airway mast cells 
One cell type prominently involved in regulation of airway contraction and responsiveness is 
the mast cell. This immune cell is found as a guardian cell in the whole body, often at interfaces 
between the interior and exterior environment such as the skin, the intestines and the lung. 
These tissue-resident mast cells are defined as having the high-affinity IgE receptor (FcεRI), 
the stem cell factor receptor KIT/CD117, and granules containing proteases, histamine and 
growth factors (23, 24).  
A discerning feature used to distinguish different mast cell populations is the protease 
content of the granules. One group is formed by tryptase-positive mast cells (MCT) and the 
other by the tryptase, chymase, carboxypeptidase A, and cathepsin G-like protease positive 
mast cells (MCTC). The MCT are mostly found at mucosal surfaces such as in the distal airways 
and the MCTC more in connective tissue including the skin. Apart from these two distinct 
groups, many intermediate mast cell types exist with different phenotypes, depending on the 
tissue in which the mast cell resides (24). 
Allergens can crosslink allergen-specific IgE-antibodies already bound to FcεRI found 
on the surface of mast cells. This initiates the release of pre-stored as well as newly synthesised 
mediators. This includes proinflammatory cytokines as for instance tumour necrosis factor α 
(TNFα) or IL-13, contractile agonist such as histamine, 5-HT, cysteinyl leukotrienes (CysLTs), 
prostaglandins and the aforementioned proteases. Not only can these compounds directly 
contract airway smooth muscle (histamine, CysLTs, prostaglandins), but they can also 
modulate airway responsiveness (TNFα, IL-13, prostaglandins) (25, 26). 
2.2.4 Main signalling pathways in controlling airway smooth muscle tone  
Three main G-coupled receptor pathways exist in airway smooth muscle that contribute to 
airway tone. Gq-signalling initiates contraction, Gs-signalling results in relaxation and Gi-
signalling can result both in airway contraction with concurrent Gs-signalling modulation and 
alteration of Ca2+ sensitivity and smooth muscle growth (27).   
2.2.4.1 Gq-coupled signalling 
Agonists that bind Gq-coupled receptors cause binding and activation of the Gq-protein 
complex to the receptor. Through this receptor-binding, several down-stream second 
messengers get activated. The most important are phospholipase C (PLC) and subsequent 
formation of inositol-1,4,5-triphosphate (IP3) and 1,2-diacylglycerol (DAG). One effect of 
these signalling molecules is that the intracellular Ca2+ concentration rises, resulting in smooth 
muscle contraction. Another result is the activation of cytosolic phospholipase A2 (cPLA2) and 
subsequent liberation of fatty acids that can serve as precursors to eicosanoid formation. Some 
important Gq-coupled receptors mediating contraction in the human airways are the histamine 
H1 receptor, the CysLT1 receptor, the muscarinic M3 receptor whilst the 5-HT2a receptor being 
important in mouse airways (27).  
2.2.4.2 Gs-coupled signalling 
When an agonist binds a Gs-coupled receptor in airways, membrane-bound adenylyl cyclase 
(AC) is activated and starts converting adenosine triphosphate (ATP) into cyclic adenosine 
monophosphate (cAMP). Increased cAMP concentrations ultimately result in decreased 
intracellular Ca2+ concentrations, thus leading to relaxation of smooth muscle in the airways 
(27). The archetypical and clinically well utilised Gs-coupled receptor in the lungs is the β2-
adrenoreceptor. Another example being the prostacyclin IP receptor (27, 28). 
2.2.4.3 Gi-coupled signalling 
Whereas Gs-coupled receptors activate AC, the activated Gi-coupled receptor does the 
opposite and thus downregulates AC-activity. It can also activate PLC and thus increase 
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intracellular Ca2+ concentrations and smooth muscle contraction. A Gi-coupled receptor found 
in the airway is the prostaglandin E receptor EP3 (27, 29).  
2.2.4.4 Other pathways 
There are also other relevant relaxant mediators and pathways that are not G-protein coupled, 
one being NO. This mediator has a function in airway relaxation through guanylyl cyclase 
stimulation resulting in cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) 
activation. A diminished neuronal NO-release has been found in a guinea pig model of allergic 
asthma, possibly leading to increased bronchial tone (30). In addition, NO-donor molecules 
have been proposed as broncho-dilating therapeutics (31). Theophylline also relaxes smooth 
muscle, though this is done via inhibition of phosphodiesterase enzymes, leading to increased 
intracellular levels of cAMP and cGMP (32).  
2.2.5 Airway hyperresponsiveness and hyperreactivity 
Airway hyperresponsiveness is the increased sensitivity to contractile agonists such as 
histamine, methacholine and CysLTs, and otherwise non-harmful external stimuli as for 
example cold, exercise and house dust mite (33). This results in increased airway contraction 
at a certain concentration of an agonist (increased potency, pEC50) and increased maximal 
contraction (increased efficacy, Emax), compared to healthy individuals (33, 34). Airway 
hyperreactivity only refers to increased maximal contraction to a contractile agonist (Emax), 
without increased sensitivity (pEC50). AHR is defined as an in vivo phenomenon, involving 
airway responses to inhaled contractile agonists in intact lungs. In cultured ex vivo explants, 
the direct response of the airway smooth muscle to an agonist may be quantified, thus assessing 
the responsiveness only on a smooth muscle level.  
AHR can be measured in individuals with asthma. This can be done either by a direct 
(methacholine, histamine) or indirect (mannitol, adenosine, allergen) challenge. Upon 
challenge, a fall in forced expiratory volume (FEV) occurs. This is often done using the 
protocol developed by Cockroft et al, involving two-minute tidal breathing of nebulised 
methacholine (35). In this protocol, the concentration that causes a 20 % fall in FEV, the PC20, 
is used as read-out and is in asthmatics generally < 8 mg/mL, whilst in non-asthmatics being > 
16 mg/mL when challenged with methacholine. Direct and indirect challenge differ in that 
direct challenge measures direct smooth muscle responsiveness to the agonist, whilst indirect 
challenge is due to activation of inflammatory cells present, releasing mediators such as 
histamine and CysLTs (34, 36).  
AHR consists of two components: chronic or persistent AHR and more variable AHR. 
The persistent AHR is seen in most patients with asthma, one contributing factor being airway 
remodelling, leading to e.g. increased smooth muscle mass, fibrosis and increased mucus 
production (33, 37). Variable AHR is related to current inflammatory status in the airways, 
being prominent during inflammation triggered by for example respiratory infections or the 
activation of mast cells by a hyperosmotic environment (33, 38).  
2.3 ANIMAL MODELS IN RESPIRATORY RESEARCH 
Multiple reasons exist for the use of animals in research, including restricted availability of 
human lung samples and fewer possibilities to perform research in humans. Therefore, use of 
both in vivo and in vitro (tissue, cells) animal models have been of great importance in 
respiratory research. Model animals often used are mice, rats and guinea pigs. Mice models are 
preferred by many researchers due to the existence of many mouse specific molecular 
biological tools such as antibodies, mouse specific cytokines and in particular, the availability 
of genetically modified strains (33). In respiratory research though, the usage of guinea pigs as 
experimental models is often preferable. This is due to the guinea pig possessing an anatomy, 
(patho)physiology and pharmacology that better resemble healthy and diseased human lungs 
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and a greater ease of performing in vivo lung measurements (33, 39). Important differences 
between the human, guinea pig and mouse respiratory tract are summarised in table 1. 
 
Table 1. Comparison of the respiratory tract in humans, guinea pigs and mice 
 Human Guinea pig Mouse 




Densely muscled Densely muscled Much less smooth 
muscle present 
 
Airway lining Thick epithelial lining 
with mucus and basal 
cells 
Epithelial lining with 
mucus and basal cells 
Epithelial lining 
thickness only 25 % 
of humans. No 
mucus producing 
cells, but club cells 
present 
 










Mast cell activation IgE-dependent IgE-/ IgG1-dependent 
 
IgE-independent 
Response to allergen Acute and chronic but 
can develop allergen 
tolerance 
Acute and chronic but 





References (33, 39, 40) 
2.4 INFLAMMATION AND IMPORTANT MEDIATORS 
Acute inflammation is a carefully programmed and protective process. It protects against 
infiltration of pathogenic bacteria, viruses, fungi or other stimuli recognised as potentially 
harmful. Classical signs of inflammation are tumor (swelling), rubor (redness), dolor (pain), 
calor (heat) and functio laesa (loss of function). On a cellular and molecular level, inflammation 
is characterised by infiltration of immune cells such as neutrophils, macrophages and later on 
T-cells, and a host of mediators being released. Examples of this include chemokines (e.g. 
CXCL8), interleukins (e.g. IL-1β and IL-13), lipid mediators (e.g., PGD2) and leukotriene B4 
(LTB4)), and acetylcholine and neuropeptides such as substance P, released by nerve-endings 
(26, 41-44). All these released substances fulfil various functions such as chemoattractant, cell 
activator or stimulant of smooth muscle proliferation and contraction (26, 42, 43).   Although 
acute inflammation exerts a protective function, chronic inflammation is part of the aetiology 
and pathophysiology of a myriad of chronic diseases (e.g. diabetes type 2, Crohn’s disease, 
rheumatoid arthritis (45-47).  
In allergic inflammation, the inflammation is preceded by sensitisation to an allergen. 
During this process, exposure to the allergen leads to antigen-presentation by dendritic cells 
and an ensuing maturation of naïve T-cells into Th2-type cells. These cells release 
quintessential type 2-cytokines: IL-4, IL-5 and IL-13. IL-5 causes an influx and survival of 
eosinophils. IL-4 and IL-13 stimulate IgE-formation by B-cells through induction of 
immunoglobulin class-switch recombination (48). Consequently, released IgE activates mast 
cells, which results in their mediators being released. 
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Repetitive exposure to an allergen can change the nature of inflammation from an acute 
response to a more chronic state. In this chronic inflammatory state, immune cells from both 
the innate immune system (e.g. innate lymphoid cells (ILC), eosinophils), and the adaptive 
immune system (e.g. different type of T-cells including Th2-type cells, B-cells), infiltrate and 
stay in affected tissues. When present in tissue, these cells interact with local epithelial and 
structural cells including fibroblasts and smooth muscle cells. Ultimately, in the airway this 
can lead to AHR and airway remodelling, the latter characterised by airway thickening, 
increased number of goblet cells, increased mucus production and an altered extracellular 
matrix containing more collagen (figure 1) (23, 48).  
 
Fig. 1. HDM exposure causes airway epithelial cells and mast cells to release e.g. cytokines, eicosanoids and 
contractile agonists which affect smooth muscle function  
2.4.1 HDM 
House dust mite (HDM) is an allergen that can cause chronic inflammation in asthma. HDMs 
are mites mostly from the Dermatophagoides genus. They are commonly found in households 
worldwide and are an important driver of allergy and asthma (49, 50). HDM extract is a mixture 
of active components containing proteases, chitinases and lipopolysaccharide (LPS) (51). 
Compared to a commonly used antigen, ovalbumin (OVA) from chicken egg white, HDM is a 
more relevant allergen in asthma. This is due to the fact that HDM itself is one of the most 
common aeroallergens found in households, as opposed to OVA, which does not play a role in 
asthma but food-allergies (52, 53). In addition, OVA sensitisation and exposure leads to a less 
broad effect. OVA induces IgE production, mast cell activation upon challenge and lung 
eosinophilia when doing repeated exposure. However, on top of these effects, HDM also causes 
epithelial barrier damage and involvement of the innate immune system (51, 54). Another 
advantage of HDM in experimental research is the greater ease to sensitise by airway exposure, 
which is more pathophysiological relevant as compared to OVA, where intra-peritoneal 





Micro-organisms, or parts thereof such as LPS found in HDM, prompt a type 1 inflammatory 
response. This causes release of TNFα which is a protein found in the membrane of innate 
immune cells that can also be found as a soluble form (56). It is a cytokine released during 
early inflammation, having a plethora of effects on different cells. When bound to the tumour 
necrosis factor 1 receptor (TNFR1), TNFα causes diverse proinflammatory effects often 
through NF-κB signalling. Examples of these proinflammatory functions are increased 
neutrophil trafficking, CXCL8 release and direct stimulation of histamine-release from mast 
cells (25, 56-58). Although less well known, TNFα also has immunomodulatory and tissue 
generative functions when signalling through the tumour necrosis factor 2 receptor (TNFR2) 
(56). In the respiratory tract, increased TNFα levels are found in patients suffering from COPD 
and asthma exacerbations and TNFα exposure causes AHR and airway hyperreactivity in vivo 
and in vitro in human and mouse tissue (59-62). A randomized, double-blind, placebo-
controlled study with a human monoclonal TNFα antibody has been performed in asthma 
patients, to test whether anti-TNFα treatment could actually improve asthma symptoms. This 
study however did not demonstrate significant improvements in airway function, though some 
sub-groups benefitted from anti-TNFα treatment (63). Nevertheless, the side-effect profile 
discouraged further development of anti-TNFα treatment regimes in asthma. 
2.4.3 IL-13 
Allergens, like those also found in HDM, induce a type 2 inflammation. IL-13 is one of the 
typical type 2 cytokines, released by different immune cells, examples being mast cells, CD4+ 
T-cells and ILC-2 cells (42, 64). IL-13 can bind the IL-4R, IL-13Rα1 and IL-13Rα2 subunits 
of the receptor complex it signals through. Receptor activation by IL-13 causes asthma-features 
including AHR and increased mucus secretion (26, 64). However, through the IL-13Rα2 
receptor sub chain, IL-13 also has reparative functions as it initiates airway epithelium wound 
repair (65). Downstream of the receptor, the signal transducer and activator of transcription 
(STAT6) pathway generally causes the effects of IL-13 in the allergic inflammation seen in 
asthma. Since the apparent critical function of IL-13 in the causation of key-features of asthma, 
several antibodies have been developed to treat patients with moderate-to-severe asthma, with 
some clinically effective (dupilumab) and others not (tralokinumab, lebrikizumab) (66-68).  
2.4.4 Eicosanoids 
Enzymatic liberation of the ω-6 PUFA arachidonic acid (AA) from the cell membrane and 
consequent actions of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes results in the 
formation of twenty-carbon long lipid mediators collectively called eicosanoids (figure 2). 
Within the eicosanoid group, there are three important branches of lipids: prostaglandins, 
thromboxanes and leukotrienes. COX-1 and COX-2 enzymes catalyse the biosynthesis of 
prostaglandins and thromboxane, whereas the 5-LOX enzyme initiates the production of 
leukotrienes. The main prostaglandins are prostaglandin E2 (PGE2), PGD2, prostaglandin F2α 
(PGF2α) and prostaglandin I2 (PGI2). Thromboxane synthase simultaneously produces 12-
HHTrE and thromboxane A2 (TXA2), which is highly unstable and quickly catabolised to 
inactive thromboxane B2 (TXB2) in the body (3). 
All prostaglandins signal through specific G-protein coupled receptors, though almost all 
of them also bind the other prostaglandin receptors, but with less affinity (69). PGE2 
preferentially binds the EP1 to EP4 receptors, PGD2 the DP1 and DP2 receptors, TXA2 the TP 
receptor, PGF2α the FP receptor and PGI2 the IP receptor. The somewhat receptor-promiscuity 
of the prostaglandins results in the fact that almost all of them can contract airway smooth 
muscle, except for PGI2, which has a relaxant effect in both airways and the vasculature (70, 
71).  
PGE2 has multiple functions that can be characterised as both pro- and anti-inflammatory. 
In the airways it induces mucus secretion, leakage of plasma in the microvasculature and it 
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modulates the airway tone (72-74). Clear anti-inflammatory actions include the inhibition of 
mast cell-mediated bronchoconstriction and inhibition of inflammation caused by IL-33-ILC2 
(74, 75). PGD2 is a notable mast cell-derived lipid mediator and plays an important role in 
many pathological processes seen in asthma. Examples are mediating antigen-induced airway 
contraction, lung eosinophilia, increased airway smooth muscle mass and release of IL-4, IL-5 
and IL-13 (76-78). However, recent data from a phase 3 trial of a DP2 antagonist, fevipiprant, 
did not improve lung function in individuals suffering from severe asthma. This suggest that 
not only the DP2 receptor, but also the DP1 and the TP receptor play a notable role in mediating 
PGD2’s effects in the lung in asthma. TXA2 and PGF2α are potent constrictors of smooth 
muscle. They induce contraction in trachea, bronchi, as well as vessels, and TXA2 also causes 
acetylcholine release (79, 80). As mentioned before, PGI2 relaxes smooth muscle in the airways 
and vasculature. Next to this, PGI2 signalling has also been implicated in the amelioration of 
allergic inflammation by reducing CD4+ T-cell activation and cytokine release (7). 
Leukotriene A4 (LTA4) and LTB4 make up one part of the leukotriene branch, with the 
LTA4-epoxide having a short half-life and quickly converted to LTB4 (81). The other group is 
the CysLTs. This group consists of leukotriene C4 (LTC4), leukotriene D4 (LTD4) and 
leukotriene E4 (LTE4). LTC4 is glutathione conjugated to the LTA4 backbone. LTD4 is formed 
through the removal of glutamine from the glutathione group of LTC4 by γ-glutamyl transferase 
and further removal of glycine by peptidases results in the formation of LTE4. 
There are two receptors for LTB4-signalling: the BLT1 and BLT2 receptor. BLT1 seems 
to be the main receptor as it shows high affinity for LTB4 binding. The BLT1 receptor is mainly 
found on immune cells such as neutrophils, mast cells and T-cells (81). Activation of this 
receptor by LTB4 results in chemotaxis of these cells, vascular leakage and indirect 
vasoconstriction (82, 83). Much less is known about the low-affinity BLT2 receptor, though in 
mast cell-mediated airway inflammation, BLT2 receptor downregulation results in decreased 
inflammation after LPS or allergen stimulation (84). Another possible role might lie in 
epidermal wound healing through activation of migration of keratinocytes. This was seen when 
the BLT2 receptor was activated not by LTB4 but by 12-HHTrE formed during TXA2 formation 
(85).                                                                                                      
The CysLTs were discovered as being the main bronchoconstrictors found in what was 
then called slow-reacting substance of anaphylaxis (86). CysLTs are one group of important 
contractile agonists found in human mast cells. They induce a slow-but-sustained contraction 
of the airways through the CysLT1 receptor. Apart from bronchoconstriction, CysLT1 and 
CysLT2 receptor activation results in permeability of the microvasculature, immune cell 
recruitment as well as increased airway smooth muscle proliferation and mucus hypersecretion 
(4). The importance of CysLTs in asthma is further illustrated by the development of the 
CysLT1-antagonist montelukast. This drug is currently used as an add-on in treatment of 
asthma patients and has further potential in other diseases as for example allergic rhinitis and 
cardiovascular disease (4). 
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Fig. 2. Simplified scheme of eicosanoid metabolism. 
2.5 SPECIALISED PRO-RESOLVING LIPID MEDIATORS 
Even though inflammation is an important mechanism, unchecked inflammation is detrimental 
and can lead to disease (87, 88). It is therefore vital that the inflammatory process is strictly 
controlled and timely stopped. This process of cessation of inflammation and return to tissue 
homeostasis is called resolution of inflammation (89). It is an active process and at least a part 
of it is mediated by lipid SPMs (89, 90). Being an SPM however is not exclusive for lipid 
mediators, as other compounds, such as the protein Annexin a1, can also have pro-resolving 
functions (91). 
 Although SPMs all carry anti-inflammatory activities, being anti-inflammatory is not 
the same as being pro-resolution. Examples of anti-inflammatory effects of SPMs are the 
reduction of neutrophil and eosinophil recruitment to the site of inflammation, production of 
cytokines by immune cells and production of reactive oxygen species (5, 92, 93). On the other 
hand, pro-resolution functions are characterised by stimulation of macrophage phagocytosis 
and efferocytosis of for instance apoptotic cells, antibody production by B-cells and reduction 
of inflammatory pain (5, 94, 95).  
SPMs are biosynthesised from both ω-6 and ω-3 PUFAs including AA, docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA) (96). In experimental settings, most SPMs are 
effective in picomolar and nanomolar ranges, making them potent mediators of resolution (97-
99). In disease settings, a few studies report decreased SPM production seen in various samples 
of patients with asthma, cystic fibrosis and Alzheimer’s disease (100-103). As DHA and EPA 
are particularly enriched in the aquatic environment, SPM production after regular intake of 
seafood or supplements might explain the beneficial effects of these ω-3 PUFAs seen (104, 
105). Nevertheless, since SPMs are readily oxidised, stable SPM analogues have been 
developed to increase bioavailability and prolong SPM exposure, thus making them a more 
viable treatment for inflammatory diseases (106-108). The most prominent SPM sub-families 






Fig. 3. Specialised pro-resolving mediators, their precursors and proposed receptors. 
2.5.1 Lipoxins 
The lipoxin family consists of two distinct members that are positional isomers. Lipoxin A4 
(LXA4;  5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid) and lipoxin B4 (LXB4; 
5S,14R,15S-trihydroxy-6E,8Z,10E,12E-eicosatetraenoic acid). Lipoxins are generated from 
AA, making them the only SPMs of the main SPM groups (resolvins, maresins, protectins and 
lipoxins) that are generated from an ω-6 PUFA (figure 3).   
The name lipoxins is derived from ‘lipoxygenase interaction products’, coined when they 
were first discovered in human leukocytes and referring to their formation by interaction of 
different LOX enzymes (109). Lipoxin formation is a concerted, transcellular effort of both 
structural as well as immune cells (110). One important pathway of lipoxin formation consists 
of the production and release of LTA4 by neutrophil 5-LOX and then further metabolism by 
12-LOX in adhered platelets, to LXA4 and LXB4 (111, 112). There is also an alternative route 
of biosynthesis where 15(S)-HETE (15(S)-hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic acid) is 
formed by 15-LOX in epithelial cells. 15(S)-HETE is sequestered by leukocytes, where 5-LOX 
may convert it into LXA4 and LXB4 (112).    
In addition to the 15(S)-enantiomers, 15(R)-lipoxins can also be produced. Normally this 
is done by cytochrome P450 enzymes, but the production can be boosted. One example is when 
acetylsalicylic acid (aspirin) is present, which irreversibly acetylates the COX-2 enzyme, 
causing COX-2 production of 15(R)-HETE and ultimately 15(R)-lipoxins in structural cells 
such as endo- and epithelial cells and immune cells such as monocytes (112). Another recent 
finding is that statins, for instance atorvastatin, usually used to lower cholesterol, appear to 
have anti-inflammatory properties (113) and S-nitrosylate the COX-2 enzyme leading to 
production of 15(R)-lipoxins and certain resolvin-series (110, 114, 115). In experimental 
settings, 15(S)- and 15(R)-lipoxins appear to exert similar functions, although differences in 
potency may exist (58, 116-118). 
Even though now generally recognised as part of the SPM family, initial experiments in 
airway tissue pointed at what can be considered a more proinflammatory profile. At its 
discovery, it was shown that LXA4 caused O2
- generation and lysosomal elastase release (109). 
It was also shown that LXA4 induced contraction of guinea pig lung strips through TXA2-
release and caused arteriolar dilation in the hamster cheek pouch (119, 120). However, after 
these findings it soon became clear that LXA4 and LXB4 also possess broad anti-inflammatory 
and pro-resolving traits.  
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Firstly, LXA4 is an agonist of the ALX/FPR2 receptor. Many of the effects of LXA4 
appear to be mediated through this receptor. For example, lipopolysaccharide (LPS, a 
component of the cell wall of gram-negative bacteria)-induced lung injury is ameliorated by 
LXA4-ALXR signalling (121) and LXA4 can dampen TNFα-mediated  pro-inflammatory 
effects such as CXCL8-release from airway epithelium (122). Moreover, decreased synthesis 
of LXA4 as well as decreased expression of the ALX/FPR2 receptor might cause defective 
resolution, which in turn can be a contributing factor to chronic inflammation as seen in airway 
diseases including asthma (8, 123) and COPD (124, 125). Secondly, LXA4 can inhibit plasma 
leakage and leukocyte adherence in the vasculature caused by LTB4, pointing to possible 
antagonistic activity for the BLT receptors (82). Thirdly, LXA4 can also displace LTD4 bound 
to the CysLT1-receptor, thereby antagonising leukotriene-induced effects, namely vascular 
leakage and airway contraction (126, 127). Finally, LXA4 exerts anti-inflammatory effects 
through the aryl hydrocarbon receptor in dendritic cells, leading to modulation of pro-
inflammatory cytokine production and inflammation (128). 
Although discovered at the same time as LXA4, much less is known about the possible 
anti-inflammatory actions and/or pro-resolving actions of LXB4. Similarly to LXA4, LXB4 can 
antagonise the prophlogistic effect of LTB4, albeit to a lesser degree (82). Also, LXB4 can also 
inhibit TNFα-release by peripheral blood mononuclear cells (PBMCs) (116). Along with this, 
LXB4 appears to have broad anti-inflammatory and pro-resolution effects in lower and upper 
airway allergic inflammation, causing decreased release of for example cytokines and IgE and 
shortening of the resolution interval (99). Interestingly, not only the innate immune system 
seems to be modulated by lipoxins, but also the adaptive immune system as LXB4 boosts IgG 
antibody production in memory B-cells, possibly through the COX-2 enzyme (94). 
2.5.2 Maresins 
As with the lipoxins, the maresin family consists of two main members: maresin 1 (MaR1; 
7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic acid) and maresin 2 (MaR2; 
13R,14S-dihydroxy-4Z,7Z,9E,11Z,16Z,19Z-docosahexaenoic acid) formed from the ω-3 
PUFA DHA. Apart from the aforementioned maresins, other maresin metabolites or 
modifications with biological effects have been described (e.g. 13(S),14(S)-epoxy-DHA, 14-
oxo-MaR1 (129, 130)). 
 Maresins were named after their discovery in macrophages, with maresin being an 
abbreviation of ‘macrophage mediator in resolving inflammation’ (131). Transcellular 
synthesis also plays an important role in the biosynthesis of these SPMs. One route in maresin-
formation is the formation of 13(S),14(S)-epoxy-DHA by platelet 12-LOX, this intermediate 
is then taken up by neutrophils to produce MaR1 (132). MaR1 can also be produced solely by 
macrophages or via uptake of the 13(S),14(S)-epoxy-DHA intermediate (129, 131).  
Immediately at its discovery, MaR1 was tested for bioactivity, showing prototypical 
SPM functions such as stimulation of macrophage phagocytosis and reduction of neutrophil 
infiltration (131). Soon after this, a more specialised function was shown in a planaria model 
of tissue generation. Here MaR1 could hasten planaria head regrowth, although the same could 
be shown for resolvin E1 (RvE1) (133). Since then, a broad range of actions and molecular 
targets have been described.  
On the receptor side, MaR1 has been found to signal through the human leucine-rich 
repeat containing G protein–coupled receptor 6 (LGR6) found on leukocytes, mediating such 
an archetypical SPM function as  phagocytosis (134). It can also influence currents generated 
by the transient receptor potential V1 (TRPV1) ion channel, thereby inhibiting inflammatory 
pain (133). 
Some actions in the lung have been described, examples being maintenance of 
permeability in lung epithelium (135), decrease of proinflammatory cytokines and CysLTs 
after harmful stimuli such as organic dust and hydrochloric acid (132, 135) and protection 
against bleomycin-induced lung fibrosis (136). In OVA-induced allergic airway inflammation 
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in mice, MaR1 levels in the lung are decreased during OVA-challenge, but increased in the 
resolution-phase, signifying the time-restricted production and release of MaR1 (137). The 
13(S),14(S)-epoxy-DHA intermediate in MaR1 biosynthesis can also interfere with the 
formation of CysLTs, as it inhibits leukotriene A4 hydrolase, decreasing formation of LTB4 
(129).    
Furthermore, MaR1 potentially has functions in both the innate and adaptive immune 
system. For example, MaR1 itself can reduce release of type 2 cytokines such as IL-5 and IL-
13 from ILC-2 cells but also through upregulating the formation of T-regulatory (Treg)-cells 
(137, 138). In addition, it can reduce the generation of TH1 and TH17 T-cell populations (137, 
139), possibly with microRNA-21 (miR-21) as a downstream effector (139). Two other 
downstream effectors of MaR1 found in bronchial epithelial cells during organic dust exposure, 
are the serum response element (SRE) found in DNA and PKC (140).  
Not much is known about MaR2. The enzymes 12-LOX from platelets and soluble 
epoxide hydrolase are known to play a role in its formation. On a functional level, typical SPM 
effects including inhibition of neutrophil infiltration and stimulation of macrophage 
phagocytosis have been shown (141). 
 A distinct group is formed by maresin-conjugates named ‘maresin-conjugates in tissue 
regeneration’ (MCTR), with three members: MCTR1 (13-glutathionyl-14-hydroxy-
docosahexaenoic acid), MCTR2 (13-cysteinylglycinyl-14-hydroxy-docosahexaenoic acid) and 
MCTR3 (13-cysteinyl-14-hydroxy-docosahexaenoic acid). MCTR1 is in effect MaR2 
conjugated to glutathione, a three-amino-acid-long peptide consisting of glutamine, cysteine 
and glycine, by leukotriene C4 synthase as well as glutathione S-transferase Mu 4 (142, 143). 
MCTR1 is converted in macrophages to MCTR2 through removal of glutamine by γ-glutamyl 
transferase (142, 144). Further removal of glycine is done by peptidases, thus forming MCTR3 
(figure 4) (142). 
Fig. 4. Biosynthesis of maresin-conjugates 
 
Since their cysteinyl-conjugation is analogues to the CysLTs, it is thought that MCTRs 
can bind the same CysLT1 receptor, but in an antagonistic fashion, thus decreasing CysLT-
induced pro-inflammatory and broncho-constrictive effects (145). There is indeed evidence 
showing MCTRs decreasing LTD4-induced bronchoconstriction, vascular leakage and 
negative ionotropic effect in tunica heart (97, 145). In resting human lung tissue, MCTRs have 
been reported to be present at approximately three times higher levels then CysLTs, a balance 
that appears to be completely shifted in diseased lung tissue where the CysLT concentration is 
ten times higher than that of MCTRs (97). The limited data so far suggests that effects can also 
be distinct for each MCTR. One example is MCTR3, which seems to be more effective in 
ameliorating OVA-induced AHR in mice, whilst both MCTR1 and MCTR3 can dampen LPS-
induced acute lung injury and AHR via different mechanisms (146, 147).  Both MCTR1 and 3 
dampen eosinophils infiltration after HDM stimulation as well (97). Apart from this, MCTRs 
also possess main SPM effects as for instance stimulation of efferocytosis by macrophages, 
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dampening neutrophil infiltration and the more specialised tissue-regenerative effect also seen 
in maresins (144, 148).  
Other than the observed effects described above, much is unknown about the MCTRs 
and a possible specific high-affinity receptor is still at large. 
2.5.3 Resolvins 
The resolvin family consists of two branches. One branch is formed by the resolvin D group, 
produced from the ω-3 PUFA fatty acid DHA. This group consists of six members: resolvin 
D1 (RvD1) to resolvin D6 (RvD6). The other branch is formed by the resolvin E group, 
produced from the ω-3 PUFA fatty acid EPA and consisting of resolvin E1 (RvE1) to resolvin 
E3 (RvE3. 
D-type resolvins were the first new SPMs discovered after the lipoxins. The name 
resolvin stands for ‘resolution phase interaction product’, with the D and E denoting their origin 
from DHA or EPA respectively (90, 149, 150). Resolvins are also formed through transcellular 
co-operation of different cells. D-series resolvin formation, at least for RvD1 to RvD4, is started 
by 15-LOX from epithelial cells. 5-LOX from neutrophils can then perform the final step to 
form RvD1-4 (149-151). As with the lipoxins, resolvin epimers can also be formed. In the case 
of the resolvin D series, aspirin acetylation of COX-2 can cause production of 17(R)-hydroxy-
DHA in the vasculature. Again, 5-LOX from neutrophils then catalyses the final formation of 
17(R)-resolvins (149, 151, 152).  E-type resolvin formation is slightly different in that the first 
step of biosynthesis is performed by either acetylated COX-2 or cytochrome P450 enzymes. 
The final step is then again performed by 5-LOX from neutrophils, or in the case of RvE3, 
12/15-LOX derived from eosinophils in mice (96, 151, 153). 
 Two receptors are important for the function of E-type resolvins. Firstly, Chemerin 
Receptor 23 (ChemR23) is important for pro-resolution effects of RvE1 in (allergic airway) 
inflammation (154, 155). In the case of OVA-induced airway inflammation, RvE1 causes 
clearance of eosinophils and antigen-specific CD4+ T-cells, in which natural killer cells (NK-
cells) might play a role as an effector cell for these pro-resolving effects (155). In addition, 
RvE1 also exerts its effect on the smooth muscle level. It can dampen increased Ca2+-sensitivity 
and U46619 (a TP receptor agonist)-induced smooth muscle contractions in rat and human 
pulmonary arteries, with or without previous exposure to TNFα and IL-6 (60, 156). Secondly, 
antagonism at the BLT1 receptor has been shown in inflammatory models (154, 157). BLT1 
antagonism by RvE1 can prevent LTB4-mediated neutrophil infiltration (154). Moreover, as 
shown in HDM and OVA mouse models of allergic asthma, RvE1 can reduce AHR, cell counts 
of eosinophils, leukocytes and macrophages, and cytokine concentrations of IL-4,IL-13 and 
IL-23 in BALF, possibly through decreasing cytokine release from lung macrophages (92, 157, 
158).  
Of the resolvin D series, 17(R)-RvD1 and RvD1 share a G-protein coupled receptor with 
LXA4: the ALX/FPR2 receptor (95, 159). Moreover, they bind the receptor with the same 
potency as LXA4 (160). The other G-protein coupled receptor involved in RvD1 signalling is 
GPR32 (161). Through these receptors, 17(R)-RvD1 and RvD1 mediate a broad pallete of anti-
inflammatory and pro-resolution functions. Both can inhibit neutrophils infiltration during 
inflammation and stimulate macrophage phagocytosis (161, 162). Downstream mediators 
important herein include microRNA’s (e.g. miR-208a, miR-219) and release of the anti-
inflammatory cytokine IL-10 (161, 163). In OVA-induced inflammation and AHR, there could 
be a difference in efficacy as 17(R)-RvD1 is more efficacious that RvD1 in reducing 
eosinophilia and AHR (164).   
Lung diseases such as cystic fibrosis or inhalation of harmful substances through 
smoking can lead to decreased endogenous production of RvD1 (102). Ensuing exogenous 
administration can reduce disease symptoms including lung destruction or development of end-
stage disease such as lung emphysema (87, 165, 166). Furthermore, RvD1, but also RvD2 and 
LXA4, can through their release by human airway epithelial cells, reduce histamine release by 
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human mast cells (18). In addition, in isolated human bronchi, RvD1 exposure has been 
reported to reduce Ca2+-sensitivity and hyperresponsiveness induced by IL-13 (98). Further 
similar actions on smooth muscle function have been shown in human and rat pulmonary 
artery, reducing again cytokine-induced Ca2+-sensitivity and contractility (156, 167). 
Less is known about the other D-resolvins. It is known that RvD2 can dampen LTD4- 
and TNFα-induced hypercontractility to histamine, methacholine (a more stable acetylcholine 
analogue) and U46619 (168). Moreover, during bacteria-induced inflammation, RvD2 reduces 
systemic inflammation, microbial burden and leukocyte trafficking. This is done through 
endothelial NO release and dampening of release of proinflammatory mediator including 
LTB4, PGE2 and several cytokines (163, 169). For RvD3 to RvD6, aside from the key SPM 
functions such as increased efferocytosis, protective effects have been shown in e.g. acid-
induced lung injury, pathological thrombosis and neuropathic and inflammatory pain (170-
175). 
In summary, ω-6 and ω-3 PUFAs can give rise to lipid mediators that could be of 
importance in lung inflammation, resolution and modulation of airway tone. If the role of SPMs 
gets further substantiated by future research, this would open up the possibility to use stable 
SPM-analogues or SPM receptor agonists to actively shut down ongoing inflammation and 
decrease symptoms in inflammatory diseases like asthma.         
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3 RESEARCH AIMS 
 
The general aim was to investigate if selected SPMs have anti-hyperreactive properties, how 
COX-inhibition results in increased airway constriction and if mast cells are necessary for 




• To examine whether a selection of specialised pro-resolving lipid mediators can 
modulate airway contractility, either by inducing contraction or relaxation or change 
the contractility to other contractile agonists   
 
• To investigate if LXA4 can reduce airway hyperreactivity induced by HDM allergen 
 
• To examine if IL-13 induces corticosteroid-resistant airway hyperreactivity in isolated 
mouse trachea and whether cysteinyl maresins are able to reduce this airway 
hyperreactivity 
 
• To investigate the mechanism underlying the way unselective COX-inhibition 
enhances OVA-induced airway constriction in guinea pig 
 
• To assess if mast cells are necessary for HDM allergen-induced airway contraction and 
if they can modulate the level of airway hyperresponsiveness after chronic HDM 





4 MATERIALS AND METHODS 
4.1 GENERAL 
Two species of animals and several inflammation models were used for the studies performed 
in this thesis. Mice were used to study the role of selected SPMs in airway contractility and 
hyperreactivity (article I, IV) or of mast cells in allergen-induced airway contraction and 
hyperresponsiveness (article II). Because of similarities with humans in airway physiology 
and pharmacology, guinea pigs were used in article III to study increased airway contraction 
after unselective COX inhibition and initial studies of direct contractile or relaxant studies of 
SPMs (not published).  
4.2 ANIMALS 
All studies performed were in accordance with the ethical permits that were obtained from the 
regional ethical review committee for experimental animal research. Guinea pigs (Dunkin-
Hartley) were obtained from Envigo and mice (BALB/c or C57BL/6) were purchased from 
Envigo or Charles River. All animals were housed in a 12-hour light/dark cycle with a 
continuous supply of food and water at their disposal. Guinea pigs were euthanised by CO2-
asphyxiation and subsequently removal of the heart. Mice were euthanised by cervical 
dislocation. 
4.3 INTRANASAL INSTILLATION 
In article I, a four-day instillation protocol was used. Mice received intranasal instillation of 
10 ng SPM one hour before the intranasal administration of 50 µg HDM, both under isoflurane-
induced anaesthesia. In article II, mice received intranasally 50 µg HDM every third day for a 
total of seven times. 
4.4 TISSUE COLLECTION AND CULTURE  
To ensure tissue viability, whole tracheae were immediately dissected out after animal 
euthanasia and kept on ice cold Krebs-Henseleit buffer until further dissection. During further 
dissection, guinea pig tracheae were divided in eight equal segments whilst each mouse trachea 
was divided in four segments. Both mouse and guinea pig segments were then immediately 
used in organ bath or myograph experiments (article I-IV) or in the case of mouse tracheal 
segments, incubated for a total of five days (article I and IV). These segments were incubated 
in 96 wells culture plates filled with low-glucose (1 g/L) DMEM supplemented with 1% 
penicillin (100 IU·mL−1) and streptomycin (100 μg·mL−1), which were placed in a humified 
incubator at 37 °C and 5% CO2. All segments were allowed an overnight equilibration period 
before they were moved to new medium, and cytokines and SPMs were added for the first time. 
In article I, SPMs were added one hour before the pro-inflammatory stimulus. In article IV 
cysteinyl maresins and cytokines were added at the same time.  
4.5 FUNCTIONAL STUDIES 
Tracheal rings were suspended in 5 mL myographs (mouse trachea) or organ baths (guinea pig 
trachea) direct after dissection or after incubation. To measure the changes in force exerted by 
the smooth muscle in the organ baths, isometric force-displacement transducers linked to a 
Grass polygraph were used. After suspension, segments were left to equilibrate for 30-60 
minutes. This was then followed by adjustment of the mechanical tension to 30 mN (guinea 
pig trachea) or 0.8 mN (mouse trachea). In studies of guinea pig trachea, the contractility of the 
tissue was tested with a concentration response curve of histamine (10 nM – 100 µM). In mouse 
trachea, this was done with 60 mM potassium chloride (KCl). Experiments in guinea pig 
trachea were ended with a maximal contraction induced by histamine (1 mM), acetylcholine 
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(1 mM) and 60 mM KCl. In mouse trachea this was done with carbachol (10 µM) and 60 mM 
KCl. 
4.6 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
Histamine was analysed by an external laboratory with an ELISA-based method (RefLab ApS, 
Copenhagen, Denmark). For the measurement of cysteinyl-leukotrienes (article III), an 
ELISA-kit was used. For the histamine analyses, glass fiber-coated microtiter plates were used. 
Samples were diluted and pipetted on the plates. After an hour of incubation at 37 °C, the plates 
were washed with distilled water, dried and closed off and sent for analysis. Cysteinyl 
leukotrienes were measured according to the manufacturers protocol (Cayman Chemical). In 
brief, a buffer was added to the wells of a 96-well plate pre-treated with a specific antibody. 
Then, standards and samples were added. Next followed the addition of a tracer of 
acetylcholinesterase bound to cysteinyl-leukotrienes and a cysteinyl-leukotriene monoclonal 
antibody. After two hours of incubation at room temperature, the plate was developed by 
washing and addition of Ellman’s reagent, containing an acetylcholinesterase substrate, and 
tracer and left to develop for 90 min. The absorption of light with a wavelength between 405 
and 420 nm was measured with a Biotek Instruments EL808 plate reader. The concentration of 
cysteinyl leukotrienes was then inversely correlated with the amount of absorbed light. Cross 
reactivity for N-methyl-LTC4 was 124%, for LTC4 and LTD4 it was 100% and for LTE4 65%. 
For other fatty acids this was <0.01%. 
4.7 MASS SPECTROMETRY 
Eicosanoid levels in samples were quantified via liquid chromatography coupled to triple 
quadrupole mass spectrometry (LC-MS/MS) (article III), as described in (176). In short, 
samples were spiked with deuterated internal standards and extracted with a pre-conditioned 
solid phase extraction cartridge. Second, solvent was evaporated and the samples were 
reconstituted in methanol. Samples were injected onto a BEH C18 column and quantitative mass 
spectral data was collected with a Xevo TQ S triple quadrupole system operating in negative 
scan mode. 
4.8 SPECTROPHOTOMETRY   
To ascertain the concentration and stability of the stocks of SPMs used, spectrophotometry was 
used. Depending on the concentration of the stocks, the sample taken from the stock was diluted 
in methanol, to achieve light absorption between 0.2 and 1.0 A.U. A blank measurement was 
used to correct all samples. The concentration was calculated with the help of the Lambert-
Beer law: A = ε x l x c. Were A is the absorption, ε the molar absorptivity, l the length of the 
optical path and c the concentration of the sample. The ε values and absorption wavelengths 
were obtained from a public spectral book with SPM spectral data (Serhan C, Lipid Mediator 
Metabololipidomics LC-MS-MS Spectra Book 2016). 
4.9 CALCULATIONS AND STATISTICS 
All data were presented as mean ± SED. Contractions were normalised to the maximal 
contraction induced by KCl, histamine and acetylcholine (guinea pig trachea) or carbachol 
maximum (mouse trachea). GraphPad Prism 8.0 software (GraphPad Software Inc., San Diego, 
CA) was used for data and statistical analyses. Non-linear regression fit was used to calculate 
pEC50 and Emax. For bolus additions, the area under the curve (AUC) was calculated. To assess 
statistical significance of multiple groups, one-way ANOVA with Dunnet’s post-hoc test was 
used, or student’s T-test in the case of two groups. When possible, paired analysis was 




5 RESULTS AND DISCUSSION 
5.1 EXPLORATION OF SPECIALISED PRO-RESOLUTION LIPID MEDIATOR 
EFFECTS IN GUINEA PIG AIRWAY AND VASCULAR TISSUE 
5.1.1 Direct smooth muscle effect of SPMs  
The SPM research field is relatively young, with most discoveries happening the last 20 years 
compared to for example the prostaglandins discovered already in the 1930s. Many animal 
studies, in particular those examining airway effects of SPMs, have been conducted in mouse 
airway tissue (157, 164, 177). The guinea pig offers another model with some advantages in 
airway research by way of similar airway anatomy and existence of similar physiology and 
pharmacology, i.e. similar agonists and receptor functions (33, 39). Therefore, guinea pig tissue 
was first used to investigate if there would be acute contractile or relaxant effects of selected 
SPMs. This would be in analogy to prostanoids being either contractile, e.g., PGF2α or relaxant, 
e.g., PGI2, PGE2, or to contractile cysteinyl leukotrienes in airways.  
To this end, a total of six structurally different SPMs were selected to screen for acute 
smooth muscle effects. The selection was made in order to have a representative SPM of each 
major group derived from different polyunsaturated fatty acids, i.e., AA, EPA and DHA (figure 
3). These representative SPMs were added in increasing concentration to baseline or 
precontracted guinea pig tracheal rings. Since these experiments were used as a screening for 
potential effects, one or two segments were dedicated to each SPM (figure 5). 
Despite the broad range of concentrations tested, picomolar up to high nanomolar, which 
is often referred to as the bio-active range of SPMs (90), no direct contractile (figure 5A) or 
relaxant effects (figure 5B) of selected SPMs were found. These data regarding SPM functions 
in airways outside the context of inflammation have not been reported before. However, LXA4 
has been tested in the same way in guinea pig airway tissue in previous investigations. In these 
investigations, it was observed that LXA4 induced contraction in lung parenchymal strips but 
not tracheal strips (178, 179), suggesting a contractile effect in vessels and not airways.  
Mechanistically, the early experiments pointed at activation of the CysLT1 receptor and 
release of TXA2 to cause the constriction observed  (120, 179). In later binding studies in cells, 
it could be observed that LXA4 and the epimer 15(R)-LXA4 displaced LTD4 from the CysLT1 
receptor (126), suggesting different mechanisms present in different cells or tissues. Chirality 
of the LXA4 molecule, i.e. LXA4 and 15(R)-LXA4, can also cause differences in receptor 
binding and biological effects (112, 180). The current data however shows no contractile or 





Fig. 5. Concentration-response curves of selected SPMs (1 pM – 100 nM) in presence of indomethacin (3 µM). 
A, addition of increasing concentrations SPMs in relaxed guinea pig tracheal rings (n = 1-2). B, addition of 
increasing concentrations SPMs in guinea pig tracheal segments precontracted with carbachol (10 or 100 nM) (n 
= 1-2). Data represent mean ± SEM. SPMs used are: lipoxins: 15(R)-lipoxin A4 (15(R)-LXA4); E-resolvins: 
resolvin E1 (RvE1); D-resolvins: resolvin D1 (RvD1) and its 17(R)-epimer 17(R)-RvD1; Protectins: protectin DX 
(PDX); Maresins: maresin 1 (MaR1).   
5.1.2 SPM modulation of agonist-induced contractions 
It was next assessed if there would be a modulatory effect of SPMs on other contractile or 
relaxant agonists in tracheal as well as vascular tissue, because of the apparent lack of a direct 
effect on smooth muscle contractile activity. It was found that maresin 1 (mar1) affected 
contractions induced by endothelin 1 and sarafotoxin 6b in tracheal and aorta tissue (figure 6), 
but not contractions induced by other contractile agonists (phenylephrine, U46619, histamine, 
figure 7). In the presence of mar1, the Emax was significantly increased (figure 6C,D) and/or 
leftward shifted (figure 6A-C). However, in the case of the concentration-response curves of 
figure 6B-D this has to be interpreted with caution since none of the curves reached the 
maximal contractile effect, thus there is still the possibility of them reaching the same Emax. 
Endothelin and sarafotoxin 6B are both non-selective endothelin receptor agonist, making an 
effect on both the ETA and ETB receptor possible.  
In guinea pig airways, ET-induced contractions are mediated by both endothelin 
receptors and can be direct, e.g., in trachea, or indirect through release of COX products, 
possibly TXA2, e.g. in lung parenchyma (181-183). It has to be noted that involvement of TXA2 
was restricted to lung parenchyma and in our experiments, indomethacin was used to remove 
a possible confounding effect of TXA2. These results seem counter-intuitive given the nature 
of SPMs and how they are proposed to resolve inflammation. Especially since endothelin 1 
could play a role in allergic airway inflammation (184, 185).  It could however, at some point 
in the resolution process, be beneficial to have an increased responsiveness to endogenous 
released endothelin 1 to for example temporarily decrease perfusion or ventilation. Because of 
our focus on allergen-induced inflammation and hyperreactivity and possible ameliorating 
effects SPMs herein, these effects were not further investigated. Future experiments are 
however needed to look into the mechanism of this effects and its possible functional relevance 
for resolution of lung inflammation.  
































































Fig. 6. Concentration-response curves of endothelin 1 or sarafotoxin 6b after 30 minutes of pre-incubation with 
protectin DX (PDX), maresin 1 (MaR1) or 17(R)-RvD1 (100 nM). A, in guinea pig aorta (n = 5-6). B, in guinea 
pig trachea (n = 2). C, mar1 in guinea pig aorta (n = 4). D, MaR1 in guinea pig trachea (n = 4). All in presence of 
indomethacin (3 µM). Data represent mean ± SEM. 
Fig. 7. Concentration-response curves after 30 minutes of pre-incubation with PDX and maresin 1 (mar1) (100 
nM). A, histamine (10 nM – 100 µM) in guinea pig tracheal rings (n = 6-9). B, U46619 (100 pM – 10 µM) in 
guinea pig tracheal rings (n = 2). C, phenylephrine (100 nM – 300 µM) in guinea pig aorta rings (n = 1-2). All in 
presence of indomethacin (3 µM). Data represent mean ± SEM 
5.1.3 MaR1 and PDX in OVA-induced airway contraction 
In the light of the important role of mast cells as in airway inflammation (186, 187) , a possible 
acute effect of MaR1 and PDX on OVA-induced mast cell activation and airway contraction 
was investigated (figure 8). No effects of these two SPMs added 30 minutes before OVA-
challenge could be seen on general OVA-induced contractions (figure 8A), nor in OVA-
induced contractions mediated by histamine (figure 8B) or leukotrienes (figure 8C).   
5.1.4 Summary  
It was found that selected SPMs do not induced contraction nor relaxation of guinea pig 
tracheal rings in the organ-bath set up. However, when pre-treating aorta rings with MaR1, a 
significant increase in sensitivity, i.e., pEC50, of sarafotoxin 6b was observed. A similar effect 
could be shown for endothelin 1-induced contraction in aorta and tracheal tissue as well. 
Nevertheless, since these are small scale exploratory studies, larger studies are warranted to 
confirm the results and explore the mechanisms involved. 
 





















































































































































































Fig. 8. Concentration-response curves of OVA after 30 minutes of pre-incubation with PDX and mar1 (100 nM) 
in guinea pig trachea. A, no indomethacin or antagonists present (n = 2-3). B, In presence of indomethacin (3 µM) 
and MK886 (10 µM) (n = 9-12). C, in presence of indomethacin (3 µM) and mepyramine (1 µM) (n = 4-6).  Data 
represent mean ± SEM 
 
5.2 ANTI-HYPERREACTIVE FUNCTION OF LXA4 AND CYSTEINYL MARESINS 
IN AIRWAY HYPERREACTIVITY INDUCED BY TNFΑ AND IL-13 IN MICE 
(PAPER I AND IV) 
It was next assessed if there were effects of selected SPMs in tracheal hyperreactivity induced 
by allergic inflammation. To this end, both exposure to HDM through intranasal instillation as 
well as to HDM or cytokines during incubation were used to induce airway hyperreactivity in 
mouse trachea. Mouse airway tissue was used to take advantage of a method developed in our 
lab to study airway hyperreactivity as well as the widespread availability of mouse specific 
cytokines. HDM was used to model a more complex allergic inflammation as HDM is a 
mixture and exposure to it causes release of both type 1 and type 2 cytokines. In addition it 
activates toll-like receptors (TLRs), depending on levels of LPS and biopolymers present in 
the HDM extract (51, 188, 189). Furthermore, by addition of TNFα or IL-13, two different 
inflammatory pathways which lead to airway hyperreactivity were modelled. TNFα is 
considered a type 1 cytokine, more involved in inflammation mediated by immune cells against 
intracellular micro-organisms (190, 191). IL-13 is a type 2 cytokine more involved in 
inflammation as part of defence against eukaryotic parasites and patho-physiologically in 
allergic inflammatory disease (190, 191). Both cytokines can also be released by mast cells 
(23).  
5.2.1 Reduction of airway hyperreactivity by lipoxins and cysteinyl maresins 
First, HDM exposure in vivo led to a pronounced upregulation of contractions induced by 5-
HT (figure 9A). This HDM-induced hyperreactivity was reduced by the DHA product 17(R)-
RvD1 as well as the AA product lipoxin LXA4. These SPMs have in common that both have 
been shown to signal through the ALX/FPR2 receptor (6, 160). The other group of SPMs 
(RvE1, MaR1 and PDX) did not reduce airway hyperreactivity. One explanation for difference 
in activity could be involvement of the ALX/FPR2 receptor, as both LXA4 and 17(R)-RvD1 
have been shown to signal through the ALX/FPR2 receptor (6, 160), but not the SPMs found 
the be inactive. Another possibility could be a different potency of the ineffective SPMs, since 
only one dose of SPM was tested. If so, to be effective as intranasal installation, both a higher 
or a lower dose of these SPMs could have been necessary, as SPM dose- or concentration-
response curves can be bell-shaped (122, 126-128). Nevertheless, this does not seem to be the 
case for LXA4 (paper I, figure 4). Another explanation could be an increased biochemical 
instability of the ineffective SPMs compared to the effective ones, leading to degradation 
before reaching their target in the lung after installation. 



















































































Fig. 9. Concentration-response curves of 5-HT in mouse trachea. A, after four days of intranasal instillation of 
selected SPMs (10 ng) one hour before challenge with HDM (50 µg) (n = 4-11). B, after four days of in vitro 
exposure to LXA4 (100 nM) added one hour before HDM (1 µg/mL) (n = 5-8). Data represent mean ± SEM  
 
Not only did HDM exposure via the intranasal route induce airway hyperreactivity, but 
the same effect was also observed with HDM exposure during four days of incubation (figure 
9B).  Nonetheless, the Emax of 5-HT was considerably lower in isolated tracheal segment after 
exposure during incubation than after intranasal installation in live animals. This could be due 
to limited availability of immune cells in the tissue explants during culturing compared to live 
animals, which would decrease the cytokines released and thus the hyperreactivity induced. In 
addition, LXA4 reduced airway hyperreactivity both when given intranasally and during 
incubation. This suggests that the anti-hyperreactive effect is mediated by receptors present on 
cells in tracheal segments, examples being epithelial cells and smooth muscle cells and airway 
resident immune cells like mast cells.  
As the TNFα inhibitor etanercept could partly reverse the HDM-induced airway 
hyperreactivity (paper I, figure 3B), it was concluded that one of the mediators released after 
HDM exposure was TNFα. Therefore, it was assessed if airway hyperreactivity induced by 
exposure to TNFα in vitro could also be inhibited by LXA4 (figure 10A). TNFα did indeed 
induce a marked increase in 5-HT responsiveness, which corresponded with previous published 
research (62). In addition, LXA4 could reduce airway hyperreactivity at three different 
concentrations (10, 100 and 1000 nM). This effect did not seem to be specific to LXA4, since 
also the positional isomer LXB4 reduced the Emax of 5-HT (figure 10B). That LXA4 can 
downregulate TNFα signalling has been observed before in human pulmonary endothelial cells 
(121). In these cells, exposure to an LXA4 releasing compound (oxidised 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphorylcholine, OxPAPC) decreased NF-κB activation, the 
important downstream protein complex involved in TNFα signalling (121). Furthermore, LXB4 
has been implicated before as being an anti-inflammatory lipid mediator in upper and lower 
allergic inflammation, not only through decreasing TNFα release from bone marrow 
mononuclear cells and stabilising mast cells, but interestingly also through accelerated decrease 
of levels of IL-4 and IL-13 and mRNA of their receptors (99). A possible receptor mediating 
the effect of lipoxins is the ALX/FRP2 receptor (paper I, table I). The results of the LXA4
 
studies are summarised in figure 13.  




























































Fig. 10. Concentration-response curves of 5-HT four days of incubation with lipoxins or cysteinyl maresins and 
TNFα (100 ng/mL) or IL-13 (100 ng/mL). A, incubation with TNFα and presence or absence of LXA4 (10 – 1000 
nM) (n = 5-21). B, incubation with TNFα and presence or absence of LXB4 (100 or 1000 nM) (n = 7-13). C, 
incubation with TNFα and presence or absence of MCTR3 (1000 nM). D-E, incubation with IL-13 and presence 
or absence of MCTR3 (n = 4-13) or MCTR1 or MCTR2 (1000 nM, n = 4-6). Data represent mean ± SEM 
 
It was also assessed if a representative SPM from another SPM family branch, namely 
MCTR3, could reproduce the dampening effect of lipoxins. However, TNFα-induced 
hyperreactivity was not affected by the presence of MCTR3 (figure 10C). This suggests 
different mechanisms of action for these structurally different SPM subgroups, even though 
MCTR3 has been found to signal through the ALX/FPR2 receptor in LPS-induced acute lung 
injury (147). 
As for the cysteinyl maresin family, though not effective in dampening TNFα-induced 
airway hyperreactivity, they were found to dampen IL-13-induced airway hyperreactivity 
(figure 10D-E). IL-13 induced a somewhat lower hyperreactivity compared to TNFα, but still 
markedly increased 5-HT-mediated airway contractions. This airway hyperreactivity was 
resistant to corticosteroids as observed in this mouse model (paper IV, figure 1C) and has been 
shown before in human airways (26). This thus makes this anti-hyperreactive action of 
cysteinyl maresins finding important, as it offers a future lead for development of treatment of 
corticosteroid-resistant hyperreactivity of the airways.   
5.2.2 Receptors involved in lipoxin and cysteinyl maresin signalling 
As stated before, one explanation for difference in effectiveness of lipoxins and cysteinyl 
maresins in TNFα or IL-13-induced hyperreactivity could be different receptors involved. For 
lipoxins, the ALX/FPR2 could play a role (paper I, table I) and for cysteinyl maresins 
circumstantial evidence suggests involvement of the CysLT1 receptor. The anti-hyperreactive 
effect of MCTR3 could be blocked when pre-incubating tracheal segments with three 
structurally different CysLT1 receptor antagonists, being montelukast, zafirlukast and 
pobilukast (figure 11A-B). Noteworthy is the difference in concentrations needed to antagonise 
the effect of MCTR3 for the different antagonists. Whilst for zafirlukast a concentration of 10 
nM would suffice, for montelukast a 100-fold higher concentration was needed to obtain the 
same effect. This does not agree with the potencies of these antagonists blocking the CysLTs, 
as the potency of montelukast and zafirlukast is more or less the same for the CysLT1 receptor 
(192). Moreover, for pobilukast the same concentration was needed as montelukast (1000 nM), 
even though pobilukast is 10-fold less potent than montelukast in cell models and lung tissue 
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(192). Though cysteinyl leukotrienes do not contract murine airways, LTD4 was used as an 
agonist for the CysLT1 receptor to examine the possible anti-hyperreactive function of this 
receptor. However, incubation with LTD4 did neither reduce IL-13-driven airway 
hyperreactivity nor did it interfere with MCTR3’s reducing effect (figure 11C-D). 
This makes it therefore unlikely that cysteinyl maresins signal through binding at the 
orthosteric binding site of the CysLT1 receptor. It is possible that there are one or more 
alternative, allosteric binding sites present on the receptor, leading to a different signalling 
cascade that is responsible for the effect seen. Another possibility would be that another 
receptor is involved, one that also binds the antagonists tested. One candidate for this was the 
GPR17 receptor (193-195), but stimulation of this receptor could not reproduce the anti-
hyperreactive effect of cysteinyl maresins (paper IV, figure 6). Furthermore, an antagonistic 
effect of cysteinyl maresins on LTD4-signalling could not be seen in mouse as well as guinea 
pig tissue (paper IV, figure 5), as was shown by others before (97). A way to confirm 
involvement of the CysLT1 receptor is future experiments with CysLT1 knock out (CysLT1
-/-) 
mice.  Until then, it remains to be proven which receptor exactly mediates the anti-
hyperreactive effect of cysteinyl maresins in airways.  
Fig. 11. Concentration-response curves of 5-HT of tracheal segments incubated with montelukast (100 and 1000 
nM), zafirlukast (10 nM), pobilukast (1000 nM) or LTD4 (100 and 1000 nM) and MCTR3 (1000 nM) and IL-13 
(100 ng/mL). A-B, zafirlukast blocks MCTR3’s protective effect at a lower concentration than montelukast (n = 
3-12) and pobilukast (n = 7-13). C-D, LTD4 cannot reproduce (n = 7-8) nor interfere (n = 3-5) with MCTR3’s anti-
hyperreactive effect. Data represent mean ± SEM 
5.2.3 Other explorations of SPM modulation of airway hyperreactivity 
Several other experiments were performed to further describe the possible mechanisms 
underlying lipoxin and cysteinyl maresin signalling in airway hyperreactivity. First, for LXA4 
it was determined if it could induce a relaxation of non-inflamed, pre-contracted tracheal rings 
(figure 12A). However, up to 100 nM LXA4, which is the concentration used in all lipoxin 
experiments, no relaxation different from vehicle was seen. This thus excludes relaxations as a 
confounding factor. The same can be stated for the cysteinyl maresins, because if a general 
relaxant function would have been present, a decrease of the Emax 5-HT should have been 
observed not only in the IL-13-driven model but also the TNFα-driven model (figure 10C-E).  
Second, the epithelium present in the trachea offers a plausible target for SPMs. Binding 
would then lead to a release of secondary anti-inflammatory, anti-hyperreactive mediators or a 
blockade of pro-inflammatory, pro-hyperreactive mediators. This would then add an extra layer 
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to the control of the inflammation and resolution balance in airway tissue. That these 
mechanisms occur has been observed for SPMs in epithelium. Both LXA4 and MaR1 are able 
to inhibit migration of neutrophils over the epithelium and inhibit release of CXCL8 or TNFα 
(140, 196). Even so, removal of epithelium from mouse trachea did not alter the hyperreactivity 
induced by IL-13 nor did it change the anti-hyperreactive effect of MCTR3 (figure 12B). It 
makes it therefore more likely that both these substances, in this particular model, exert their 
effects on the smooth muscle cells. Though effects on other cells have not been excluded, such 
as effects on immune cells present or other structural cells.  
Modulation of airway contractility in non-inflamed mouse tracheal segments was also 
assessed, before continuing into the inflammatory models already described. This was done in 
analogy to the studies in guinea pig tissue. In these studies, it was found that cysteinyl maresins, 
when added at 30 minutes before performing concentration-response curves of carbachol, 
caused a significant (MCTR2 and MCTR3) half-log shift of the pEC50 as well as a trend 
towards reduction of the Emax (non-significant, p = 0.07 for MCTR1 and 3 and p = 0.17 for 
MCTR2, figure 12C). Something which could not be seen for U46619-mediated contractions 
(figure 12D).  
Fig. 12. Acute effects of LXA4 and cysteinyl maresins and role of the airway epithelium segments. A, 
concentration-response curve for LXA4 in PGF2α (3 µM) pre-contracted mouse tracheal segments (n = 7-10). B, 
effect of four-day incubation of epithelium positive (Epi+) and epithelium denuded (Epi--) mouse tracheal rings 
with MCTR3 (1000 nM) and IL-13 (100 ng/mL, n = 6-8). C-D, concentration-response curve of carbachol and 
U46619 after 30 minutes of pre-incubation with cysteinyl maresins (100 nM) in mouse tracheal rings. Data 
represent mean ± SEM 
  



































































































































In mouse trachea, HDM, TNFα and IL-13 cause a pronounced increase in airway 
responsiveness to 5-HT. Several types of SPM can counter this airway hyperreactivity. LXA4 
does this in HDM and TNFα-induced hyperreactivity when given via intranasal instillation, as 
well as during incubation of tissue explants. RvD1 and 17(R)-RvD1 can replicate this effect 
when given intranasally before HDM and LXB4 during incubation together with TNFα. The 
ALX/FPR2 receptor might play a role in lipoxin signalling in these experiments, but not the 
epithelium (summarised in figure 13).  
Cysteinyl maresins can reduce IL-13-induce hyperreactivity, which could be specific to 
this cytokine since they do not reduce hyperreactivity induced by TNFα. Cysteinyl maresin 
signalling is inhibited by known CysLT1 antagonists, though stimulation of the receptor by 
LTD4 does not modulate 5-HT mediated contractions (summarised in figure 14). This opens 
the possibility that cysteinyl maresins signal through a previously unknown allosteric site of 
the CysLT1 receptor, and thus points at a possibly anti-inflammatory function of this receptor. 
Fig. 13. Schematic summary of the main findings found in paper I and important remaining questions. HDM 
causes release of TNFα, which in turn causes airway hyperreactivity. This hyperreactivity can be reduced by LXA4.  
 
Fig. 14. Schematic summary of the main findings found in paper IV and important remaining questions. Cysteinyl 
maresins, known also as MCTRs, dampen IL-13-induced airway hyperreactivity but not TNFα-induced 
hyperreactivity.  CysLT1 antagonists block the anti-hyperreactive effect of cysteinyl maresins, but the CysLT1 
agonist LTD4 does not have any dampening effect, nor does the GRP17 agonist MDL29951. 
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5.3 PGD2-DP1R AS AN AUTO-INHIBITORY AXIS IN MAST CELL MEDIATED 
AIRWAY CONSTRICTION (PAPER III) 
One part of the effect of SPMs are their anti-inflammatory actions. But they are not the only 
lipid mediators having anti-inflammatory effects in airway tissue. Even though prostanoids are 
generally known for their pro-inflammatory functions, they also have been found to mediate 
anti-inflammatory effects. A well-known example is PGE2, which can inhibit activation of mast 
cells in human lung tissue, thus reducing antigen-induced bronchoconstriction (74). Another 
example is PGI2, which not only causes smooth muscle relaxation, but can also inhibit release 
of cytokines and interacts with immune cells from the innate as wells as the adaptive immune 
system (7, 197). This relates to the work in this thesis, which uncovers a similar mechanism for 
PGD2 as for PGE2 in OVA-induced constriction of tracheal rings from sensitised guinea pigs. 
5.3.1 PGD2 is produced by the COX-1 enzyme in mast cells and inhibits 
OVA-induced guinea pig airway constriction 
In the initial experiments it was verified that a bolus dose of OVA induces a marked contraction 
tracheal segments from OVA-sensitised guinea pigs (figure 15) (198). This contraction was 
reduced over time, though did not return to basal tension for 90 minutes. Furthermore, when 
the tissue was pre-treated with the unselective COX-inhibitor indomethacin, OVA-exposure 
induced an increased contraction which was sustained over time. However, when the FLAP/5-
LOX enzyme was blocked by MK-886, this resulted in a decreased contraction that returned to 
baseline tension within 45 minutes. 
Three main groups of substances released from mast cells can be distinguished when 
analysing the concentrations of lipid mediators released after OVA exposure and blockade of 
COX-enzymes or the 5-LOX enzyme. First, unselective COX blockade as well as COX-2 
blockade led to an almost complete inhibition of release of PGE2, PGF2α and the PGI2 
breakdown product 6-keto-PGF1α (paper III, figure 2), with no effect of FLAP/5-LOX 
blockade. This thus showed that these lipids are formed by the COX-2 enzyme. Second, 
unselective COX blockade, but not COX-2-specific blockade nor FLAP/5-LOX blockade, 
inhibited release of PGD2, TXB2, and 12-HHTrE. This led to the conclusion that the latter lipids 
are formed by the COX-1 enzyme. Finally, the concentrations of the leukotriene LTB4 and the 
contractile cysteinyl leukotriene LTE4 were decreased by FLAP/5-LOX blockade, unchanged 
by COX-2-specific blockade but increased by unselective COX-inhibition. As unselective 
COX inhibition, but not COX-2-selective inhibition, increased the concentration of the 
contraction-inducing LTE4, it was concluded that the substance mediating the inhibiting effect 
seen in figure 15 must come from COX-1, thus being PGD2 or TXB2 products. 
Fig. 15. Traces and area under the curve (AUC) of tracheal segments exposed to a bolus dose OVA (100 µg/mL) 
and presence or absence of indomethacin (3 µM) of the FLAP/5-LOX inhibitor MK-886 (10 µM). Data represent 
mean ± SEM with n = 5 
 
Two inhibitors were used to specifically inhibit haematopoietic prostaglandin D2-
synthase (PPCA) or thromboxane A synthase (ozagrel) to further define which COX-1-
produced lipid mediator was responsible for the dampening effect observed (figure 16). 
Blockade of PGD2 formation by PPCA resulted in an increased and sustained contraction after 
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OVA exposure (figure 16A), an effect that was similar to that observed in figure 15. However, 
blockade of the TXA2/TXB2 pathway had no effect on OVA-induced contractions (figure 16B). 
Consequently, the reduction of OVA-induced contraction was attributed to PGD2.  
In the following investigations the inhibitory function was confirmed, and the receptor 
involved was further investigated. To start with, tracheal segments were incubated with three 
concentrations PGD2, after which OVA concentration-response curves were made (figure 
17A). These experiments could show that PGD2, concentration-dependently, decreased OVA-
induced contractions. Second, the dampening effect of PGD2 could be reproduced when using 
another DP1 receptor agonist (BW 245c), but not when using the DP2 receptor agonist 15(R)-
15-methyl PGD2 (figure 17B). Finally, the involvement of the DP1 receptor was further 
confirmed by usage of a DP1 antagonist (MK-524), which concentration-dependently inhibited 
the DP1 agonist (figure 17C). 
Fig. 16. A, traces and AUC of guinea pig tracheal segments exposed to a bolus dose OVA (100 µg/mL) and 
presence of SQ-29,548 (1 µM) and presence or absence of the haematopoietic prostaglandin D2-synthase inhibitor 
PPCA (1 µM). B, concentration-response curve of OVA in presence of SQ-29,548 (1 µM) and presence or absence 
of the thromboxane A synthase inhibitor ozagrel (10 µM). C, Release of TXB2 after OVA and ozagrel (1-10 µM).  





Fig. 17. OVA concentration-response curves in guinea pig trachea in presence of indomethacin (3 µM) and SQ-
29-548 (1 µM). A, in presence of PGD2 (0.1 - 10 µM). B, in presence of the DP1 receptor agonist BW 245c (0.1 – 
10 µM) or the DP2 receptor agonist 15(R)-15-methyl PGD2. C, in presence of BW245c (10 µM) and presence or 
absence of the DP1 receptor antagonist MK-524 (10 – 1000 nM). Data represent mean ± SEM with n = 5-8 
 
In another experimental setting it was confirmed that DP1 receptor activation with BW 
245c leads to a decreased constriction after OVA exposure. Here, increased concentrations of 
BW 245c led to decreased release of histamine and cysteinyl leukotrienes after addition of a 
bolus OVA, with a concomitant decreased Emax of the induced contraction (figure 18A-C). 
Also, the DP1 receptor antagonist MK-524 reversed the dampening effect of BW-524 on OVA-
induced contractions (figure 18A) as well as reversing the decreased release of cysteinyl 
leukotrienes mediated by the DP1 agonist (figure 18C). 
Fig. 18. Traces of OVA responses in guinea pig trachea with simultaneous release of histamine and cysteinyl 
leukotrienes in presence of indomethacin (3 µM), BW 245c (0.1 - 10 µM) and presence or absence of MK-524 
(0.1 µM). A, OVA-induced contraction. B, histamine release after 15 min. C, cysteinyl leukotriene release after 





A following investigation was started to further prove that endogenously released PGD2 
mediated this inhibitory effect as well. To this end, an OVA concentration-response curve and 
bolus dose exposure were performed with the presence of the DP1 receptor antagonist MK-524 
present (figure 19). Here it was shown that PGD2 is released upon OVA stimulation, and this 
released PGD2 inhibits further contraction. This is done through the DP1 receptor by inhibiting 
release of the contractile mediators histamine and cysteinyl leukotrienes. 
As a final series of experiments, it was excluded that DP1 receptor stimulation with PGD2 
could modulate (dampen Emax or right shift the pEC50) histamine or LTD4-induced contractions 
or that it could cause relaxation in tracheal segments (paper III, figure 7). If so, this would have 
been an alternative explanation for the decreased contractions seen. However, the DP1 receptor 
agonist did not change histamine or LTD4-induced contractions, nor did it induce a relaxation 
of pre-contracted tracheal segments. 
Fig. 19. Concentration-response curve and traces of OVA responses with simultaneous release of histamine and 
cysteinyl leukotrienes in presence of indomethacin (3 µM) and MK-524 (0.1 µM). A, OVA-induced contraction. 
B, OVA bolus induced contraction. C, histamine release after 15 min. D, cysteinyl leukotriene release after 90 
min. Data represent mean ± SEM with n = 5-6 
5.3.2 Summary 
Despite the over 40-year-old knowledge that unselective COX-inhibition augments lipid 
mediator release and bronchoconstriction induced by antigen (199, 200) and that certain asthma 
patients experience increased bronchial constriction after NSAID usage (201), no mechanism 
underlying these observations has been proven without reasonable doubt. Though increased 
availability (shunting) of arachidonic acid from the COX-pathway to the 5-LOX-pathway has 
often been proposed, the experiments presented here now shown that this actually does not 
seem to be the case. PGD2 is formed by the COX-1 enzyme in OVA-sensitised guinea pigs and 
released after OVA-exposure of isolated tracheal segments. This endogenously released PGD2 
acted through the DP1 receptor, resulting in a decreased release of histamine and leukotrienes 
and ultimately reduced OVA-induced contractions. This effect could be replicated by the 
exogenous administration of PGD2 to the organ-bath set up. PGD2 had no effect on histamine 
or LTD4 mediated contractions nor did it induce relaxation.  
This thus offers evidence for a PGD2-driven negative feedback loop present in mast cells 
when stimulated by antigens, similar to the inhibitory effect of PGE2 on human mast cell-
dependent bronchoconstriction, mediated by the EP2 receptor (summarised in figure 20). 
Further investigation is warranted to examine if the effect of PGD2 also is present in human 
mast cells. The dampening effect of PGD2 might be somewhat surprising since PGD2 is 
considered a pro-inflammatory mediator (202, 203). However, this proves that anti-
inflammatory functions should not only be expected within the SPM group of lipid mediators, 
but within the prostanoid and even the leukotriene group as well (204). Moreover, it should be 
kept in mind that possible detrimental effects can occur when blocking the production of a 




Fig. 20. Schematic summary of the main findings found in paper III. OVA causes mast cell activation in mast 
cells from OVA-sensitised guinea pigs. Mediators are released upon activation and induce contraction. However, 
PGD2 also decreased further release of contractile mediators from mast cells through DP1 agonism. This ultimately 
dampens OVA-induced contractions, thus making PGD2 serve as a negative autocrine signal for guinea pig mast 
cells. 
 
5.4 ROLE OF MAST CELLS AND MAST-CELL DERIVED 5-HT IN AIRWAY 
HYPERRESPONSIVENESS (PAPER II) 
Mast cells are known effector cells for allergen-induced bronchial constriction. In paper III of 
this thesis, it has been described that lipid mediators mediate important functions in airway 
constriction by mast cells. However, not only lipid mediators mediate contractile and anti- or 
pro-inflammatory responses, but also other substances such as 5-HT have inflammatory and 
pro-contractile functions (23, 205-207). 5-HT causes contraction of isolated mouse tracheal 
segments, as also observed in paper I and IV. Histamine however does not induce contraction 
in mice airways, as opposed to in human or guinea pig airways (26, 198).  
It is known that HDM-sensitisation and challenge causes mast cells to migrate to areas 
in the airway close to the epithelium and smooth muscle (208). Nevertheless, the functional 
implications of this migration are not clear and often investigated with usage of knock-out mice 
having lost c-kit expression, which causes mast cell depletion (208). Even so, this effect is not 
always mast cell specific, making it possible that the phenotypes observed are not attributable 
solely to the loss of mast cells (209). This investigation therefore served to dissect out mast cell 
mediated effects on airway hypercontractility, using another mast cell depleted mouse strain: 
Cpa3Cre/+. These mice express Cre-recombinase instead of mast cell carboxypeptidase A3 
(Cpa3), which more specifically initiates mast cell death. 
5.4.1 Consequences of different genetical modifications of mast cells on 
airway hyperreactivity 
HDM was administered every third day for 18 days to induce airway inflammation and 
hyperreactivity in mice (paper II, figure 1A). Repeated administration of HDM could induce a 
10-fold increase in potency of carbachol, without effecting the Emax (figure 21A). In addition, 
there was no difference in carbachol-induced contractions between mast cell depleted (CpaCre/+) 
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and non-depleted (Cpa+/+) mice. Differences could be observed when looking at 5-HT-
mediated contractions (figure 21B). First, as expected, HDM-exposure induced an airway 
hyperreactivity seen as increased airway contractions in tracheal segments from both mast cell 
depleted and non-depleted mice.  
Second, segments from mast cell-depleted mice displayed an increased potency of 5-HT 
in mediating contractions, compared to those from non-depleted mice. Though at first glance 
this effect might be unexpected, an explanation could be that a constant release of 5-HT from 
mast cells causes a level of tachyphylaxis of the 5-HT2a receptor, which is not happening in 
airways from mast cell depleted mice.  
To demonstrate that HDM causes activation of mast cells, which in their turn release 
contractile substances like 5-HT and acetylcholine, tracheal segments were exposed to a bolus 
HDM (figure 21C). The absence of mast cells completely inhibited the HDM-induced 
contraction. Moreover, mice lacking functional Fc receptors due to loss of the γ-subunit 
(Fcer1g-/-) were used to prove that HDM-induced contractions were due to mast cells activation 
by cross-linking of IgE receptors (Fc receptors). Indeed, loss of the Fc-receptor also resulted in 
a complete loss of HDM-induced contractions (figure 21D).   
It was shown that loss of the major form of mast cell tryptase (Mcpt6-/- mice) does not 
influence the constriction induced by HDM (figure 21E). The question left then, was which 
mediator actually caused the contractions seen. Therefore, segments were incubated with the 
5-HT2a receptor antagonist ketanserin and the non-selective muscarinic receptor antagonist 
atropine (figure 21F). Both ketanserin as well as atropine almost completely inhibited HDM-
induced contractions. This effect of both atropine and ketanserin has been found before (210, 
211). It is still under debate which mediator, 5-HT or acetylcholine, actually activates mast 
cells and which one is released after antigen-exposure and caused airway constriction. It has 
been ascertained that mouse mast cells contain and release 5-HT (212). This released 5-HT has 
been hypothesised to activate airway epithelium, which would then release acetylcholine. This 
acetylcholine would then mediate the actual contraction (210).  Nevertheless, usage of a murine 
OVA model also showed an epithelium-independent mechanism, in which 5-HT from mast 
cells caused release of acetylcholine, which again would contract the airways (211).  
5.4.2 Mast cell activation by the M3 receptor 
The mechanisms of antigen-induced mast cell activation and airway contractions were 
dissected out in further experiments. These experiments resulted in four lines of evidence:  
 
1. Precision cut lung slices (PLCS) showed a diminished contraction after HDM exposure 
in CpaCre/+ mice (paper II, figure 4). 
2. Mast cells synthesised 5-HT and released this upon HDM exposure, also in the lower 
airways (paper II, figure 4). 
3. HDM-sensitised mice displayed methacholine mediated airway hyperresponsiveness, 
which was blocked by ketanserin and reduced after loss of mast cells (paper II, figure 
5).  
4. Mast cells expressed the M3 receptor and release 5-HT upon methacholine stimulation 
(paper II, figure 6). 
   
These data show that it is indeed possible that in an allergic inflammatory setting, antigen 
causes 5-HT-release from mast cells, which in turn initiates release of acetylcholine from 
parasympathetic nerve endings causing contraction of airway smooth muscle and further 
activation of mast cells. Still, another mechanism could also be at play. It could be that HDM-
sensitisation and exposure causes a neuronal reflex leading to release of acetylcholine, which 
in turn stimulates 5-HT release from mast cells that then binds and activates the 5-HT2a receptor 
present on the airway smooth muscle. The importance of neuronal tissue in inflammatory 
airway diseases and mast cell activation is known and affected by inflammation itself (213-
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217). This would also be in line with data on cytokine-exposed isolated tracheal tissue from 
unsensitised mice, in which 5-HT was observed to directly contract smooth muscle, with only 
a minor component being secondary release of acetylcholine from nerve endings (62) (paper I, 
figure 6). Finally, other inflammatory cells could also be involved in the effects seen. Mast 
cells are not the only cells that can modulate airway responsiveness, as for example 
eosinophilic lung infiltration also increases 5-HT responsiveness, again through interactions 
with nerves (218). 
Fig. 21.  Concentration-response curves, traces and Emax of HDM (50 µg) responses in different mouse mast cell 
KO models. A-B, carbachol and 5-HT in mast cell deficient (Cpa3Cre/+) and mast cell non-deficient (Cpa3+/+) mice. 
C, HDM in wildtype (WT) and Cpa3Cre/+ mice. D, HDM in WT and Fc-receptor deficient (Fcer1g-/)- mice. E, HDM 
in WT and major form of mast cell tryptase deficient (Mcpt6-/-) mice. F, Effect of atropine and ketanserin in 




Mast cells in the lower and upper airways play an important role in antigen (HDM)-induced 
contractions. Their activation by HDM, which is a mixture of different enzymes, other proteins, 
LPS and more, results in airway smooth muscle contraction, but also enhances airway 
hyperresponsiveness. Frequent release of 5-HT might decrease 5-HT responsiveness of airway 
smooth muscle.  Loss of mast cells and loss of their Fc receptors led to a complete inhibited 
response upon HDM exposure. Mast cells expressed the M3 receptor and stimulation by 
acetylcholine and methacholine resulted in release of 5-HT and increased airway 
hyperresponsiveness. The released 5-HT from mast cells might release further acetylcholine 
from parasympathetic nerve endings but could also directly contract the airways. This is 
summarised in figure 22. 
 
Fig. 22. Schematic summary of the main findings found in paper II and remaining questions. HDM causes airway 
contraction and hyperresponsiveness in HDM-sensitised mice. This contraction might be due to Fc receptor 
mediated release of 5-HT, which causes nerve-endings to release acetylcholine (Ach). This Ach might then 
contract the airway smooth muscle. Alternatively, HDM causes neuronal release of Ach, which activates mast 




6 GENERAL DISCUSSION 
Two key pathophysiological processes that underpin many symptoms of asthma are increased 
contractility of the airways and airway inflammation. Though two distinct features, it is airway 
inflammation that can lead to the development of airway hyperreactivity (26, 36, 62, 198, 219). 
The beneficial effects of corticosteroids in the management of asthma symptoms also relate to 
their anti-inflammatory effects (220). Nevertheless, corticosteroid-resistant, airway 
hyperreactivity in severe asthma exists (26, 221). In addition, blockade or dampening of some 
pathways of inflammation, does not lead to complete resolution of airway inflammation.  
Lipid mediators play important roles in mediating airway inflammation and modulation 
of the contractile state of the airways in asthma (222). They possess pro-inflammatory (76, 
223), pro-contractile (86) as well as anti-inflammatory and pro-resolving functions (6). 
Therefore, these mediators constitute an attractive target for future treatment options to resolve 
ongoing inflammation in asthma and other chronic-inflammatory diseases. Main emphasis was 
put on the SPM group of lipid mediators and how they modulate airway contractility because 
of their anti-inflammatory and anti-hyperreactive potential. First the guinea pig was used, as it 
offers some advantages over mice in airway research due to e.g., similarities in receptors 
present in lung tissue, physiological control of airway contractility and pathophysiological 
mechanisms (224). 
It was first investigated if SPMs would influence the contractile state of non-inflamed 
guinea pig airway tissue, having in mind the direct contractile effects of many lipid mediators 
from the AA-COX/LOX-pathways. Not many acute effects of selected SPMs were observed, 
except for the finding that maresin 1 potentiated sarafotoxin 6b- and endothelin 1-mediated 
constrictions in tracheal and aorta rings. Apart from this, the main conclusion was that either 
the guinea pig is not a good model for SPM and resolution biology in the airways, or SPMs are 
not directly involved in the contractile state of airway smooth muscle, at least not outside the 
inflammatory milieu. Which is not an all too surprising finding since SPMs are formed as part 
of the late inflammatory response (90), when a return to katabasis is needed again. Though this 
would not have excluded a direct relaxant effect in analogy to PGI2, which is an anti-
inflammatory lipid mediator as well (225).      
However, given the essentially negative results in guinea pig and previous observations 
pointing at SPMs primarily being effective during inflammation, a more appropriate 
experimental setting was needed. Even so, without the widespread availability of guinea pig 
specific cytokines, investigations of SPM biology is difficult. Mouse-specific cytokines 
however are readily available, and several pro-inflammatory stimuli are prone to induce airway 
hyperreactivity (62, 212, 226, 227). HDM, TNFα and IL-13 all induced airway hyperreactivity 
that is observed as an increased contraction to 5-HT. Increased contractions of 5-HT are of 
interest as 5-HT is the mediator that is released from mouse mast cells during allergic 
inflammation (212). A role that is served by histamine and leukotrienes in human mast cells 
(23, 228). 
Several SPMs were found to have an anti-hyperreactive activity in different models of 
airway hyperreactivity. Lipoxin activity was observed across HDM and TNFα-induced 
hyperreactivity, suggesting a mechanism in which lipoxins interfere with TNFα signalling 
(figure 13). This was further supported by the fact that part of the effect of HDM could be 
blocked by the TNFα inhibitor etanercept, suggesting TNFα release after HDM exposure. A 
mechanistic explanation would be that TNFα binding leads to upregulation of the 5-HT2a 
receptor. Another would be a more general smooth muscle effect of lipoxins, such as 
upregulation of L-type Ca2+ channel upregulation. This that has been shown for CXCL8 and 
TNFα-induced airway hyperreactivity before (229). The anti-hyperreactive actions could be 
related to ALX/FPR2 signalling, as ALX-FPR2 agonists (lipoxins and RvD1) were effective 
in blocking HDM-induced hyperreactivity and an ALX-FPR2-antagonist partly blocked the 
anti-hyperreactive effect of LXA4. A downstream mediator affected by LXA4 signalling might 
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be NF-κB. This important effector protein complex of TNFα, has been found to be inhibited 
by LXA4 before (174, 230, 231).  
LXA4 was not 100% effective in blocking hyperreactivity. This might have been due to 
the concentrations used, duration of effect of SPM vs TNFα, chemical stability or other 
unknown factors. Moreover, the LXA4 function could also be specific to TNFα-NF-κB 
signalling in airway tissue. Furthermore, etanercept did not completely block airway-
hyperreactivity after HDM exposure. HDM thus not only caused airway hyperreactivity 
through release of TNFα, but possibly also through release of other pro-contractile cytokines. 
This could be the type 2 cytokine IL-13. Airway hyperreactivity induced by IL-13 was found 
to actually be dampened by another group of SPMs: the cysteinyl maresins (figure 14). The 
cysteinyl maresin activity seemed to be restricted, in that they were not able to interfere with 
the pro-contractile effect of TNFα. This action of cysteinyl maresins was novel. Even more 
intriguing was the way the CysLT1 receptor seemed to be involved, namely not through its 
orthostatic binding site.  
Due to the shared cysteinyl moiety, research focus has been on the possible competitive 
antagonism of cysteinyl maresins for the CysLT1 receptor (97, 145), However, our 
investigations showed that cysteinyl maresins could not shift the LTD4 concentration-response 
curve in guinea pig tracheal tissue. Despite this, the anti-hyperreactive effect of cysteinyl 
maresins was inhibited by CysLT1 receptor antagonists in mouse tracheal tissue. Others have 
found before that MCTR1 or MCTR3 could prevent LPS-induced lung or cardiac disfunction 
(146, 147, 232). Interestingly, one investigation pointed at cysteinyl maresin activity on another 
receptor: the ALX/FPR2 receptor with involvement of the airway epithelium (147). Though in 
our own experiments, epithelium removal had no effect on the anti-hyperreactive effect of 
MCTR3. A protective function of the CysLT1 receptor has been found before. Here, CysLT1 
receptor knock-out mice showed an increased airway hyperresponsiveness in a model of 
irritant-induced asthma (204). Other experiments looking at CysLT1 activation should further 
clarify if and how cysteinyl maresins bind to this receptor, possibly by biased agonism or via 
orthosteric modulation. It could be of interest as well to investigate if an ALX/FPR2 receptor 
antagonist is able to interfere with cysteinyl maresin signalling and if lipoxins can repeat the 
effect of cysteinyl maresins in this model.  
Guinea pig tracheal tissue was used to clarify the mechanism, mediator and receptor 
responsible for increased OVA-induced airway constriction after unselective COX-inhibition 
(figure 20). Mast cell exposure to OVA-induced PGD2 production by the COX-1 enzyme and 
subsequent release.  PGD2 then functioned as negative feedback signal to mast cell via the DP1 
receptor. DP1 receptor activation of mast cells led to a decreased release of histamine and 
cysteinyl leukotrienes, resulting in decreased airway contraction. This mechanism was similar 
to the auto-inhibitory effect of PGE2 on mast cells present in human lung tissue via the EP2 
receptor, which also resulted in decreased levels of histamine and leukotrienes and ultimately 
dampened airway constriction (74).  
PGD2 is well known for its pro-inflammatory role in type 2 inflammatory asthma, being 
associated with a decreased lung function, increased exhaled NO and lung eosinophilia (222), 
often through the DP2 (CRTH2) receptor (76). An in-built anti-inflammatory function into an 
otherwise more pro-inflammatory mediator could serve as to prevent excessive inflammation 
and associated damage. This balancing act is thus seen in prostaglandin signalling, but LXA4 
could be considered in the same way. Most arachidonic acid metabolites possess predominantly 
pro-inflammatory traits, but simultaneous release of LXA4 balances these, thus preventing 
excessive inflammation.  
This also brings the attention to the usage of drugs like NSAIDs. Complete blockade of 
enzymes important for the production of mediators involved in many processes in the body, 
such as COX-enzymes, does not always go unpunished. In this case, there is a group of 
aspirin/NSAID intolerant asthmatics suffering from asthma worsening upon ingestion of these 
compounds, often referred to as aspirin-exacerbated respiratory disease (AERD) (233). 
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Moreover, NSAID intake leads to hospitalisations due to gastro-intestinal bleeding and 
respiratory symptoms (234) and other effects include increased risk of heart and renal failure 
(235, 236). Of course, efforts have been made to prevent this by usage of for example gastro-
protective drugs like proton-pump inhibitors and the development of COX-2-specific 
inhibitors, but these have cardio-vascular side-effects as well (237).  
Next to LOX enzymes, COX enzymes contribute to the formation of SPMs as well. In 
this case, COX inhibition could result in a decreased production of SPMs leading to the 
hampering of the resolution process (90). Result of this would be a continuation of 
inflammation into a more chronic form, leading to increased inflammation-associated damage. 
The development of stable SPM analogues or selective agonists of their receptors could 
therefore be a better treatment strategy, compared to NSAID-mediated blockade of pro-
inflammatory pathways. SPM based drugs would then be used to induce resolution of chronic 
inflammation underlying inflammatory diseases. Other options are modulation of receptors. 
An example would be a combination of a DP2-receptor antagonist to prevent allergen-induced 
airway inflammation plus a TP-receptor antagonist to prevent associated airway contractions 
(198). An inhaled, combined EP2-EP4 receptor agonist could be another method as to decrease 
mast cells activation and airway hyperreactivity in allergic airway disease (74). 
The finding that mast cell depletion in genetically modified mice resulted in significantly 
reduced allergic airway inflammation and hyperreactivity, further substantiated the importance 
of mast cells in allergic inflammation (figure 22). However, the presence of mast cell during 
repeated intranasal administration of HDM was not necessary for an increased pEC50 of 
carbachol in isolated tracheal segments. Furthermore, mast cell presence resulted in a decreased 
5-HT-mediated contractility in isolated segments, compared to those from mast cell depleted 
mice. This thus pointed at the existence of a possible counter-balancing mechanism leading to 
a decreased airway contraction, possibly being receptor tachyphylaxis.  
Another main finding was the existence of the M3-receptor on mast cells, as well as other 
immune cells like eosinophils and neutrophils. In mouse mast cells, M3-activation would lead 
to release of 5-HT. This receptor was also found on human mast cells and led to Ca2+-
mobilisation. Though not done now, it would have been interesting to investigate if M3 receptor 
stimulation would have resulted in the release of histamine and leukotrienes. If so, this would 
have pointed at a role of acetylcholine from nerve endings in activation of mast cells and airway 
contractions. It has been shown before that such an interaction between mast cells and nerves 
can indeed lead to inflammation and airway contraction (211, 214, 218). Nevertheless, vagal 
nerve ending are also implicated in the timely resolution of (airway) inflammation. Vagal nerve 
stimulation can activate certain cells involved in lung injury repair (238) or induce release of 
SPMs (239). What can be concluded is that mast cells are necessary for allergen-induced 
airway constriction and mast cell activation leads to aggravated airway hyperresponsiveness.    
The general aim of this thesis was stated as: to investigate if selected SPMs have anti-
hyperreactive properties, how COX-inhibition results in increased airway constriction and if 
mast cells are necessary for antigen-induced contraction and airway hyperreactivity. The 
investigations showed indeed that diverse lipid mediators had anti-hyperreactive activities in 
cytokine and antigen-induced airway hyperreactivity. Provided that these findings can be 
translated in humans as well, stable lipid mediator analogues or other receptor antagonists 
might offer future treatment strategies for inflammatory airway diseases such as asthma. In 
doing so, special focus should be placed on modulation of airway mast cell activity to further 







The main conclusions that can be distilled from this thesis are: 
 
• The SPMs tested do not cause acute contraction or relaxation of guinea pig tracheal 
tissue. Nonetheless, maresin 1 and protectin DX might potentiate ETa/ETb-mediated 
contractions. 
 
• LXA4 has an anti-hyperreactive effect that dampens HDM and TNFα-induced airway 
hyperreactivity when given intranasally or during incubation of tracheal segments. 
 
• Cysteinyl maresins are able to reduce steroid-resistant airway hyperreactivity induced 
by IL-13. This effect is possibly achieved through an allosteric binding site of the 
CysLT1 receptor. 
 
• Lipoxins, cysteinyl maresins and their receptors are potential new targets for the 
development of drugs modulating airway responsiveness. 
 
• Prostaglandin D2 released by guinea pig mast cells serves as an auto-inhibitory signal 
via the DP1 receptor, reducing release of the contractile mediators histamine and 
cysteinyl leukotrienes and ultimately airway constriction. 
 
• Lung mast cells are imperative for HDM-induced airway constriction and increase 
airway hyperresponsiveness possibly through mast cell-nerve interactions. 
 







And so, the final round of writing begins… 
  
Almost five years ago my adventure here in Stockholm began. It was the same month as it is 
now and the same kind of weather, grey and wet. The idea of coming to live and work here 
was both daunting and exciting as well.  The first person I met back then, was also going to be 
one of the most important persons for the rest of my PhD. Jesper Säfholm, thank you for the 
past years. Our first talk during my job interview immediately made me feel at ease and helped 
me to make the choice to start my adventure here in Stockholm. Your enthusiasm for research 
and cheerfulness have been most welcome, especially when my research (again!) was not going 
according to plan. It also made our trips to London and Edinburgh much more pleasant. Next 
to your scientific knowledge you also have great science-fictional ;) knowledge which helped 
me to find great series to watch when not at work. And most of all, thanks for making the 
switch to Swedish with me, otherwise I would never have achieved my long-held dream to 
speak the Swedish language. 
Research is never done alone, and I was in the lucky position to be guided by an 
additional team of three supervisors.  Craig Wheelock, despite your role maybe not the one 
imagined when I first started my PhD-studies, your guidance on a more general scientific and 
personal level has been very much appreciated. I also really liked the way you talked more 
about the philosophical side of science and how it made you happy if others joined the 
discussion. Mikael Adner and Sven-Erik Dahlén, thank you both for sharing your vast 
knowledge of our research area with me and giving me the scientific freedom to make my 
contribution to the field. I have thoroughly enjoyed the occasions of science-in-a-relaxed- 
atmosphere during conferences and group meetings. And to all supervisors, thank you for 
choosing my name from all the application letters five years ago. 
During my years I have been part of two different research groups: Experimental Asthma 
and Allergy Research and the Wheelock lab/Integrative Molecular Phenotyping. With the 
members of the Wheelock laboratory, I have shared many a Monday morning during our lab 
meetings. Even though you might not have seen me in your lab so much, you all had to listen 
to my worries about my experiments and if I would ever be able to defend my thesis. Thank 
you for this, Tony, Hildur, Javier, Romanas, Isabel, Pei, Alessandro, Beninia and past lab 
members Stacey, Cristina, Alexander, Evangelia, Shama and David.  
Efter tre år av övning hade det varit konstigt om jag inte hade skrivit åtminstone några 
meningar på svenska. När det gäller det svenska språket så borde jag verkligen tacka Ingrid 
Dehlin och Anne Petrén. Tack för att ni lyssnade och svarade på alla mina frågor kring ert 
fina språk. Våra snackstunder är något jag verkligen kommer att sakna. Dessutom får jag inte 
glömma nämna hjälpen jag har fått med labbsaker och beställningar! 
The relation between food and health has always been an interest of mine. How lucky I 
was to get you Johan Kolmert as one of my close colleagues. I really enjoyed our 
conversations about food and science. For me, you are what I would call a real scientist. 
Curious, open to other opinions, rational and never afraid to ask a question. For the sake of 
science, I hope you will continue as a researcher! 
Ooooohhh Jielu, after all these great moments we had in the lab, our time working 
together is now coming to an end. I am so glad that I met you and that we had all these nice 
talks regarding our scientific worries but also about Sweden, the country we love both. I think 
you are quite a special, unconventional, and intelligent person. Hopefully, one day, you will 
show me the beautiful countryside of China and otherwise I will come and visit you in Sweden. 
Big thank you to all the other members of our lab: Anna James, though we have not 
seen each other so much during the years, it was always nice talking to you, especially as it 
gave me the chance to listen to your beautiful English pronunciation. Maria Belikova, you 
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were a nice colleague to work with and always handy to have around, since everything was 
clean and in order when you were there ;). Good luck with the rest of your PhD-studies and 
becoming a specialist doctor. Maria Mikus, what a pity you have never had the time to take a 
look at my experiments! Have a wonderful time with your new-born son and your husband. 
Anna-Karin Johnsson, you are relaxed and knowledgeable, really great to have around and a 
big asset for your new lab. Roelinde Middelveld, de gesprekjes die wij hadden vond ik altijd 
heel erg fijn. Hoewel jij al 20 jaar in Zweden woont, en ik Nederland niet per se erg miste, 
vond ik het toch leuk om een soort nederlandse verbinding te hebben. Op deze manier kon ik 
natuurlijk mijn Nederlands ook nog een beetje onderhouden! Veel succes op je nieuwe 
werkplek en hopelijk komen we elkaar nog eens tegen, hetzij in Nederland of Zweden. 
Lingling and Caijuan, good luck with finishing up your PhD-studies or in the case of Caijuan, 
the upcoming two years of experiment here in Sweden. Both of you are lucky to always be able 
to count on help from Jielu. And Anita Sydbom, this last year with all the Zoom meeting, you 
have become this person that is always sitting in such a cosy home :). Thank you for sharing 
your knowledge of your favourite molecule histamine. Also, past lab members Alexandra Ek, 
Joshua Gregory, Patricia Ramos Ramírez and my great help Malin Noreby. Lastly, the 
people from the ENT-group which whom we shared our corridor during the early days of my 
PhD-studies: Susanna Kumlien Georén, Cecilia Drakskog, Sandra Ekstedt, Eric 
Hjalmarsson, and past members Lotta Tengroth and Nele de Klerk. 
Big thank you to Jenny Hallgren Martinsson and Erika Haide Mendez Enriquez for 
the great scientific collaboration we had, and the help I got to make my defence happen. 
Olivia Larsson, I have enjoyed and appreciated our talks over at AFL. Good luck with 
your busy job. 
And thank you to my mentor, Anders Tengholm. The research project at your 
department was in itself already a really fun experience. On top of that, it also paved the way 
for me to find a great place in Sweden to obtain my PhD.   
Sannaliina Nikula, you have been a great and relaxed landlady and ‘far away’ friend. I 
would wish for everybody to have such a nice landlady.  
Natuurlijk ook een bedankje voor jou, Eline Stoutjesdijk. Ik waardeer onze gesprekjes 
altijd zeer en ze helpen mij altijd weer vooruit. Succes met je verdere opleiding tot klinisch 
chemicus en wie weet worden we ooit collega’s.  
En mijn promotieplek had ik denk ik nooit gekregen zonder de hulp van Martina 
Schmidt. Bedankt voor de positieve aanbevelingsbrief waardoor ik een tijd onderzoek heb 
kunnen doen in Uppsala. Dit heeft daarna zeker meegeholpen bij het verkrijgen van mijn 
promotieplek. 
Dirk en Marleen, René, Marloes, Juna en Vera. Bedankt voor alle gezellige barbecues 
de afgelopen jaren. En niet te vergeten de ontelbare cappucino’s en chai-lattes bij de Doppio. 
En dan mijn lieve schoonfamilie in Nederland. Hannie en Arno, het is alweer 15 jaar 
geleden dat ik jullie heb leren kennen. Vanaf het begin hebben we het altijd met elkaar kunnen 
vinden en zijn jullie mij erg dierbaar geworden. Nog maar vijf jaar geleden zaten we bij jullie 
op de bank te dromen van een promotie en leven in Zweden, en nu is het alweer voorbij. 
Bedankt voor alle steun gedurende deze tijd en voor de vele ontspannende weekeinden in jullie 
warfstermolenparadijsje!  En natuurlijk ook bedankt voor de andere familieleden: Sanneke, 
Franke, Marijn en Melle en Michiel, Lisette en Wander. Het is altijd fijn om met jullie te 
praten over van alles en nog wat, of in het geval van Marijn en Melle, even lekker te stoeien. 
Leafste heit en mem, no binne jimme ek oan bar fanselts. Sûnder jimme hie ik hjirre net 
stûn. Letterlik net, mar wichtiger noch troch al jimme stype en oanmoedigingen ha ik alles 
berikke kint wat ik graach woe. Ek at we inoar net hielendal begrype hat it jimme nea 
tsjinholden om foar my klear te stean en my te helpjen. Mear kinne jin tink ik net freegje fan 
jins âlders. Jimme binne geweldige, beskeiden, hurdwurkjende, ferstanniche en foaral 
oergryslik leave minsken. Dankewol foar alles.  
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En wis ek myn suskes en alle oanhing dy garre is de lêtste jierren: Wilma, TW, Aniek 
en Janne en Sjoukje, Folkert, Mette en Jilles. Alle gesellige famyljegearkomsten at we wer 
yn Nederlân wiene en de grappige filmkes fan de bern binne tige wolkom west yn dizze drokke 
jierren. 
Om te eindigen met mijn liefste Maarten. Wat een ontzettend leuke, bijzondere maar 
ook soms moeilijke vijf jaren hebben we (bijna) achter de rug. Wie had gedacht dat na onze 
vele vakanties in Zweden en Stockholm, we hier ook echt een tijd zouden gaan wonen. Je hebt 
altijd interessante en doordachte ideeën en meningen, je bent onzettend lief en hebt mij altijd 
ondersteund. Hopelijk kunnen we nu weer een beetje tot rust komen en straks neerstrijken in 
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